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ABSTRACT: Endogenous long-chain metabolites of vitamin E
(LCMs) mediate immune functions by targeting 5-lipoxygenase (5-
LOX) and increasing the systemic concentrations of resolvin E3, a
specialized proresolving lipid mediator. SAR studies on semi-
synthesized analogues highlight α-amplexichromanol (27a), which
allosterically inhibits 5-LOX, being considerably more potent than
endogenous LCMs in human primary immune cells and blood.
Other enzymes within lipid mediator biosynthesis were not
substantially inhibited, except for microsomal prostaglandin E2
synthase-1. Compound 27a is metabolized by sulfation and β-
oxidation in human liver-on-chips and exhibits superior metabolic
stability in mice over LCMs. Pharmacokinetic studies show
distribution of 27a from plasma to the inflamed peritoneal cavity
and lung. In parallel, 5-LOX-derived leukotriene levels decrease, and the inflammatory reaction is suppressed in reconstructed
human epidermis, murine peritonitis, and experimental asthma in mice. Our study highlights 27a as an orally active, LCM-inspired
drug candidate that limits inflammation with superior potency and metabolic stability to the endogenous lead.
■ INTRODUCTION
Deficiency of vitamin E causes a dysfunctional immune
response, degenerative diseases, and potentially atherosclerosis
and Alzheimer’s disease.1−5 The discovery that the vital
antioxidant vitamin E mediates immune functions through
endogenous long-chain metabolites (LCMs) recently revived
research on this field.6−8 LCMs are produced from α-
tocopherol (1a) and other vitamin E forms (1b−d, 6a−d)
by hepatic ω-oxidation, yielding ω-alcohols and then ω-
carboxylic acids, which are excreted via bile and feces,
shortened by successive β-oxidations, or conjugated with
sulfate or glucoronate for urinary elimination.7,8 The LCMs α-
T-13′-CH2OH (9a) and α-T-13′-COOH (12a) were detected
at low nanomolar concentrations in human plasma, albeit with
strong variation between individuals.6,8,9 These differences in
1a metabolism may provide an explanation for the mixed
outcomes of human vitamin E intervention studies8,10,11 and
open the door toward personalized pharmacotherapy. Notably,
LCMs reach the highest concentration in the liver, which
correlates with the recently confirmed clinical efficiency of 1a
in nonalcoholic fatty liver disease (NAFLD).12
We have shown that 12a accumulates within immune cells at
sites of inflammation, such as the inflamed peritoneal cavity of
mice, limits the inflammatory reaction in murine peritonitis,
and suppresses bronchial hyperreactivity in experimental
asthma by targeting 5-lipoxygenase (5-LOX).6 LCMs bind to
an allosteric site between the 5-LOX catalytic and regulatory
domains and inhibit the enzyme at concentrations that are
reached in plasma for 12a.6
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5-LOX initiates the biosynthesis of powerful immunomo-
dulatory lipid mediators from polyunsaturated fatty acids that
are released from membrane phospholipids by cytosolic
phospholipase (cPL)A2.
13 5-Lipoxygenase-activating protein
(FLAP) transfers arachidonic acid to 5-LOX at the nuclear
membrane, where leukotriene (LT)A4 is synthesized via 5-
hydro(pero)xyeicosatetraenoic acid (5-H(P)ETE) as an
intermediate.14 LTA4 is converted to either the potent
chemoattractant LTB4 or cysteinyl-LTs that elevate vascular
permeability and trigger smooth-muscle contraction.15−17 LTs
are central for asthma and allergic rhinitis and contribute to
dermatitis, inflammatory liver disorders, neurodegenerative
diseases, cardiovascular disease, and cancer.14,15,18−21
5-LOX is also involved in the biosynthesis of lipoxins,
resolvins, and other specialized proresolving mediators that
orchestrate resolution, pathogen clearance, and tissue regen-
eration,22,23 but the impact of 5-LOX in this process differs
between immune cell populations.14,24 Remarkably, 12a
strongly increased systemic resolvin E3 levels in mice during
the resolution phase, whereas the 5-LOX inhibitor zileuton,
which is in clinical use for asthma therapy, did not show a
comparable effect.6 These findings suggest that 12a, besides
suppressing acute inflammation, promotes resolution, which
would be a major advantage in treating chronic inflamma-
tion.22
Additional targets besides 5-LOX were proposed to
contribute to the anti-inflammatory effectiveness of LCMs.
Garcinoic acid (δ-TE-13′-COOH, 13d), a potential LCM with
unknown physiological relevance in humans, has agonistic
activity on specific nuclear receptors, such as pregnane X
receptor and peroxisome proliferator-activated receptor γ, a
mechanism that is partially shared by other LCMs.25,26 Of
note, nuclear receptor activation by compound 13d has been
proposed to diminish Alzheimer’s disease progression by
interfering with β-amyloid oligomerization and deposition.27
Further immunomodulatory targets were reported for LCMs at
supraphysiological concentrations. 13′-Alcohols and 13′-
carboxylic acids derived from 1a, δ-tocopherol (1d), and δ-
tocotrienol (6d) suppress lipopolysaccharide (LPS)-induced
signal transduction in macrophages, thereby lowering cytokine
release and the expression of proinflammatory enzymes, such
as inducible nitric oxide synthase (iNOS) and cyclooxygenase
(COX)-2.28−30 Moreover, the 13′-carboxylic acid of δ-
tocopherol (12b), but not α-tocopherol (12a), reduces
enzymatic COX-2 activity,6,31 and tocotrienol-derived 13′-
carboxylic acids (13a−d) inhibit microsomal prostaglandin E2
synthase (mPGES)-1,32 an inducible enzyme that is function-
ally coupled to COX-2 and responsible for excessive
prostaglandin (PG)E2 formation during inflammation.
33,34
The in vivo relevance of COX-2 and mPGES-1 inhibition is
unclear,35 but their moderate inhibition might be beneficial to
buffer substrate redirection from LT to PG biosynthesis.36
The recent insights into bioactive vitamin E metabolites
promise access to a new generation of 5-LOX-targeting drugs
that suppress inflammation without impairing but instead
triggering resolution. LCMs potently inhibit 5-LOX, benefi-
cially adjust lipid mediator profiles, and are enriched in
immune cells at inflammatory sites.6 As endogenous
metabolites, they might be less afflicted with toxicity than
zileuton and diverse clinical candidates targeting 5-LOX.37
Challenges for drug development were, however, the limited
knowledge about pharmacophores, the elusive oral availability,
and the rapid hepatic LCM metabolism. We here explored the
structural requirements for 5-LOX inhibition, taking differ-
ences in cellular uptake into account, and identified α-
amplexichromanol (α-TE-12a′,13′-diCH2OH, 27a), a highly
potent allosteric 5-LOX inhibitor, which combines a favorable
pharmacological profile with oral availability and superior
metabolic stability. Compound 27a accumulates in immune
cells, is efficiently distributed to inflamed regions, and shows
anti-inflammatory effectiveness in experimental models of
atopic dermatitis in vitro and murine peritonitis and bronchial
hyperreactivity in vivo.
■ RESULTS
Design and Semisynthesis of Chromanols Inspired
from Bioactive Vitamin E Metabolites. Compound 13d
was extracted and purified from Garcinia kola nuts according to
a previously described method with an optimized yield
compared to the literature.39,40 Chromanols from the
amplexichromanol series (10e, 27c, 27d) were isolated from
Garcinia amplexicaulis stem barks.41 Both α- and β-forms (13a,
Scheme 1. Preparation of δ-(Z)-Garcinoic Acid 13ea
aReagents and conditions: (a) TosCl, Et3N, DCM, rt., 2.5 h, 72%; (b) 2-iodoxybenzoic acid, DCM/DMSO (9:1), 40 °C, 6 h; (c) NaClO2,
H2NSO3H, 2-methyl-2-butene, 1,4-dioxane/H2O (1:1), 0 °C, 2 h, 72% (2 steps); (d) NaOH, MeOH, 70 °C, 3 h, 95%.
Scheme 2. General Preparation of Formyltocopherols 2−4a
aReagents and conditions: (a) NCS, MeOH, rt., 2 h, 95%; (b) MgCl2, Et3N, (CHO)n, THF, reflux, 75%; (c) MOMBr, nBuLi, THF, −5 °C, 2 h,
80%.
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13b, 27a, 27b) were obtained from the corresponding δ-forms
of the garcinoic acid (13d) and amplexichromanol (27d) series
through a two-step strategy, which involves the preparation of
the mono- or bis-Mannich bases and their reduction with
sodium cyanoborohydride.42,43 δ-(Z)-Garcinoic acid 13e has
been previously isolated from Clusia grandiflora, more
specifically from fruits, and subsequently characterized.44 In
the current study, it was prepared from the corresponding
alcohol 10e extracted from the stem barks of this plant and also
found in G. amplexicaulis (Scheme 1). Two oxidative steps,
namely, 2-iodoxybenzoic acid-mediated and sodium chlorite-
mediated, were applied to the tosyl-protected precursor 49.
Final hydrolysis led to 13e with 51% overall yield over four
steps.
Formyl derivatives are key intermediates to access a wide
variety of functionalized polyphenols (e.g., coumarins,
chalcones). Therefore, a MgCl2-mediated formylation was
applied to vitamin E derivatives from different series
(tocopherol, tocotrienol, garcinoic acid, amplexichromanol),
leading to 2, 3, 7, 8, 33, 34, and 4738 (Scheme 2). Benzyl
alcohol 46 was isolated due to an incomplete redox process
(Scheme 3).45 C5-hydroxymethylation was also evaluated
using reagents that prevent formylation such as paraformalde-
hyde and boric acid. Starting from 70 allowed the preparation
of 48.46 Compound 3 was either protected as a methoxymethyl
acetal 4 or oxidized through a Pinnick oxidation leading to the
corresponding carboxylic acid 5.47 Similar conditions applied
to aldehyde 5439 led to 15b and then 15a bearing a truncated
11-carbon long side-chain (Scheme 4). Aldehydes 33 and 34
were further involved in a condensation step with β-
carbonylesters toward coumarin-tocotrienol hybrids 41−43
(Schemes 3 and 5).48
To increase the flexibility of the tail of the side chain and
thus potentially improve the binding affinity of the
Scheme 3. General Preparation of 33, 41, 46, and 47a
aReagents and conditions: (a) see Alsabil et al.;38 (b) MgCl2, Et3N, (CHO)n, THF, reflux, 33% for 46, 36% for 47; (c) ethyl acetoacetate,
piperidine, EtOH, reflux, 89%.
Scheme 4. General Preparation of 15a, 15b, 19a, 19b, 20−22, and 25a
aReagents and conditions: (a) MeI, NaHCO3, DMF, MW 120 °C, 45 min, 93% for 52, 85% for 25; (b) NaH, MeI, DMF, 0 °C, 1 h, 67% for 53;
(c) Mg, MeOH, rt., 16 h, 66% for 21, 72% for 22; (d) NaOH, MeOH, 70 °C, 4 h, 91% for 19b, 87% for 20, 77% for 15b; (e) TMDA, (CHO)n,
1,4-dioxane, MW 140 °C, 40 min and then NaBH3CN, EtOH, reflux, 14 h, 62% for 19a, 75% for 15a; (f) see Ville et al.;
39 (g) NaClO2, H2NSO3H,
2-methyl-2-butene, 1,4-dioxane/H2O (1:1), 0 °C, 2 h, quant.; (h) see Viault et al.
47
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corresponding ligands, reduction of the conjugated double
bond of garcinoic acids was envisioned. Among different
conditions (enzymatic, cobalt-, or copper hydride-catalyzed)
reported in the literature and applied to conjugated esters or
amides, the use of magnesium in dry methanol was the sole
successful approach leading to 21 and 22 after a non-
stereoselective three-step strategy from 13d (Scheme 4).49−53
Hydrogenation of 10a, 10c, and 27d, respectively, yielded 9a,
9b, and 26 as diastereoisomeric mixtures (Scheme 5).54 A
similar conclusion can be drawn for 12a and 12b, previously
prepared from 13a and 13d.28
Ruthenium-catalyzed cross-metathesis, applied to a toco-
trienolic starting material bearing three double bonds along its
side chain, could be considered a powerful combinatorial tool
leading in one step to various tocotrienol analogues with
shorter side chains. The efficiency of cross-metathesis is known
to be dependent on the substitution and the electron density of
the alkene reagents. In the present study, three ruthenium
catalysts (Grubbs-II, Hoveyda−Grubbs-I, and Hoveyda−
Grubbs-II), tolerant with electron-poor alkenes and mono-
or disubstituted with various functional groups, were evaluated
under different heating conditions and reaction times in
deuterated chloroform.55 Yields were estimated through HPLC
analysis of a crude aliquot from the reaction mixtures. This
process confirmed that optimized conditions were both
reagent- and catalyst-dependent. Therefore, experimental
conditions vary for the metathesis reactions involving tosylated
δ-tocotrienol 57 and methyl acrylate, methyl methacrylate, or
2-methylene-1,3-propanediacetate. Methyl methacrylate was
employed to mimic the substitution pattern similar to the
garcinoic acid series (Scheme 6). Methyl acrylate led to
desmethyl analogues of 13d with various side-chain lengths.
Scheme 5. General Preparation of Amplexichromanol Analogues 26, 31, 32, 35−40, 42−45, and 48a
aReagents and conditions: (a) (CH3CO)2O, pyridine, rt., 24 h, 85%; (b) Pd/C 10% wt, EtOAc, rt., 40 min, 52%; (c) MeONa, MeOH, rt., 40 min,
99%; (d) (CHO)n, N-methylpiperazine, MeOH, reflux, 48 h, 92%; (e) (CHO)n, secondary amine [= pyrrolidine (35); dimethylamine (36);
morpholine (37); piperidine (38); N-methylpiperazine (39)], MeOH, reflux, 5 h, 90% for 35, 90% for 36, 95% for 37, 95% for 38, 92% for 39; (f)
see Alsabil et al.;38 (g) ethyl acetoacetate (for 42) or diethyl malonate (for 43), piperidine, EtOH, reflux, 1−3 h, 93% for 42, 90% for 43; (h) ethyl
bromobutyrate (for 67) or bromoacetamide (for 69), NaH, THF, 0 °C, 4 h, 70% for 67, 66% for 70; (i) succinic anhydride, Et3N, THF, rt., 20 h;
(j) LiOH 10%, THF, rt., 3 h, 85%; (k) PTSA, THF, 1 h, 60% for 31, 72% for 32; (l) 4-nitrobenzaldehyde dimethyl acetal, PTSA, THF, reflux, 5 h,
78%; (m) H3BO3, (CHO)n, AcOH, toluene, reflux, 12 h, 55%.
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The third aforementioned alkene reagent, 2-methylene-1,3-
propanediacetate, helped prepare amplexichromanol ana-
logues. Eventually, 14, 16−18, 28, and 29 were synthesized
in our group through a cross-metathesis approach56 similar to
the one recently reported by Gujarathi et al.57 Tosyl ester was
used as a protecting group of the phenol function rather than a
silylated ether. This choice initially aimed at achieving one final
deprotection step of all protecting groups. Practically such a
strategy was successfully applied to the syntheses of 28 and 29
with the parallel removal of acetates and tosylate groups of 62
and 63. On the other hand, a two-step deprotection sequence
was employed to access 14, 16, and 17.
Mannich bases, a chemical class with a wide structural
variety, exhibit a broad spectrum of biological activities,
including antitumoral, anti-inflammatory, antimicrobial, and
antiviral properties.58,59 Besides obtaining structural insights
from docking studies, we considered optimizing the
physicochemical properties of pharmacologically relevant
candidates. Water solubility may be further enhanced by
adding a protonable group. Therefore, aminomethylation
through the Mannich reaction was explored. This strategy
has already been applied to 6d to provide C5-aminomethylated
analogues with an antitumoral potential.46 In the current study,
several mono- and bis-Mannich bases have been prepared
either in the garcinoic acid (23,32 246) or in the
amplexichromanol (35−40) series following classical exper-
imental conditions (Scheme 5).
Alkylation of the phenol function was potentially associated
with a loss of 5-LOX binding affinity for the corresponding
tocotrienolic ethers.6 Based on reported synthesis methods for
the development of redox-silent antitumoral vitamin E
analogues, two ethers (32, 45)60 and one ester (31)61 bearing
both a hydrogen-bond donor and acceptor with different linker
lengths were semisynthesized and evaluated (Scheme 5).
Structural Requirements for 5-LOX Inhibition. SAR
studies on chromanols as 5-LOX inhibitors were performed
both for the isolated human recombinant enzyme (cell-free
assay) and in activated human polymorphonuclear leukocytes
(PMNL, cell-based assay). ω-Oxidation of tocopherols (1a−d)
and tocotrienols (6a−d) at the 16-carbon side chain led to
potent 5-LOX inhibitors with a 13′-hydroxy or 12a′-
hydroxymethyl group (9a, 9b, 10a−e),6 carboxylic acid
(12a, 13a−d),6 carboxamide,42 or methoxycarbonyl substitu-
ent (21) (Tables 1 and S1, Schemes S1 and S2). The 5-LOX
inhibitory potency was modulated by methyl substitution at
the chromanol core, although not always in the same direction
for tocopherols (1a−d), tocotrienols (6a−d), and derivatives
with the modified side chain.6 Thus, 13d is the most potent
C13′-carboxylic acid to inhibit 5-LOX, whereas ω-alcohols
(9a, 9b, 10a−c) are slightly less potent but also less restricted
to side-chain unsaturation (9a vs 10a, 9b vs 10c), the site of ω-
oxidation (C13′ or 12a′; 10d, 10e vs 13e), and chromanol
methylation (e.g., 10a vs 10c in comparison to 13a vs 13d for
the 5-LOX enzyme).6 Dihydroxylation of one double bond
within the side chain was detrimental (27d vs 30) (Tables 2
and S1, Schemes S1 and S2).
We have shown that immune cells strongly accumulate
LCMs, with the endogenous vitamin E metabolite 12a being
more efficiently enriched than 13d.6 As a consequence, 12a
suppressed 5-LOX product biosynthesis in PMNL better than
13d, which was the more potent enzymatic 5-LOX inhibitor
(Table 1, Schemes S1 and S2). This gain of potency in PMNL
was limited to side-chain saturated derivatives and not evident
for the respective α-garcinoic acid 13a. Together, substantial
differences in the SARs of 5-LOX inhibition exist between cell-
free and cell-based assays. The challenge was to enhance 5-
LOX inhibition while maintaining an efficient uptake of the
vitamin E-inspired compounds into immune cells.
Starting from 13a−d as promising leads, we focused on the
length and functionalization of the side chain and explored
options for chromanol substitution. Both inhibition of cell-free
5-LOX activity and the biosynthesis of 5-LOX products in
activated PMNL were addressed (Table 1, Schemes S1 and
S2). In a first step, we varied the side-chain length (14, 15a,
15b, 16) and found that inhibition of 5-LOX activity
consistently decreased with shorter chain length within the
δ-series (14, 15b, 16), both in cell-free and in cell-based assays.
Side-chain shortening of the α-derivative 13a (from C13 to
C11) yielding 15a was instead tolerated. We then addressed
side-chain methylation, saturation, and chain length and found
that 5-LOX inhibition was impaired for the desmethyl
analogue at the C12 position (14) as well as by saturation of
the Δ11′,12′ double bond (19a, 19b) and absent when
truncated to C5 side chains (17, 18). Together, the natural
LCM 13d excels in 5-LOX inhibition within this series of side-
chain scaffold modifications.
Scheme 6. General Preparation of 14, 16−18, 28, and 29a
aReagents and conditions: (a) TosCl, Et3N, DCM, rt., 4 h, 60%; (b) for 58−60 methyl acrylate Grubbs-II catalyst, CDCl3, reflux, 3 days, 10% for
58, 30% for 59, 49% for 60; (c) for 61 methyl methacrylate Hoveyda−Grubbs-II catalyst, CDCl3, MW 120 °C, 2.5 h, 21%; (d) LiOH, THF/
MeOH/H2O (3:1:1), 40 °C, 16 h; (e) KOH, MeOH, reflux, 6 h, 16% for 14, 31% for 16, 17% for 17, 20% for 18, 53% for 28, 57% for 29; (f) 2-
methylene-1,3-propanediacetate, Grubbs-II catalyst, CDCl3, MW 120 °C, 2 h, 27% for 62, 38% for 63.
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Next, we investigated whether ω-oxidation at both C13′ and
C12a′ potentiates 5-LOX inhibition. In fact, 12a′/13′-
dihydroxylated tocotrienol analogues (27a−c) belonging to
the amplexichromanol series inhibited cell-free 5-LOX (27a:
Table 1. Inhibition of Human Isolated 5-LOX and 5-LOX Product Formation in Activated PMNL by Garcinoic Acid-Derived
Compounds (12a−25)e
aIC50 values (μM).
bResidual activities (% control) at 1 μM compound concentration. cResidual activities (% control) at 3 μM compound
concentration. dHighlighted data (gray) are from Pein et al.6 n.d., not determined. eAll values are given as mean ± standard error of the mean
(SEM) of single determinations obtained in 3−6 independent experiments.
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Table 2. Inhibition of Human Isolated 5-LOX and 5-LOX Product Formation in Activated PMNL by Amplexichromanol-
Derived Compounds (26−48)e
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IC50 = 0.11 μM) better than ω-carboxylic acids (13a−c),
except for the δ-derivative 27d, which was less potent than 13d
(Tables 1 and 2, Schemes S1 and S2). We hypothesize that the
methylation pattern of the chromanol core (as found in natural
vitamin E forms) impacts cellular uptake and thus 5-LOX
inhibition. In support of this hypothesis, the inhibitory activity
of α-amplexichromanol 27a further increased in PMNL (IC50
= 0.04 μM), thereby exceeding the potency of the endogenous
metabolite 12a (IC50 = 0.08 μM).
6 The β- and γ-analogues
27b and 27c maintained their activity in the cell-based assay,
whereas δ-amplexichromanol 27d was less effective, which
again highlights the strong influence of chromanol substitution
on cell-based 5-LOX product formation. Shortening to C9
(28) or C5 (29) side chains was detrimental, especially in the
cell-based assay, and also side-chain saturation of 27d yielding
26 was not tolerated. Ring closure of the 12a′,13′-diol to
substituted 1,3-dioxans (44−48) was explored because we
previously found that bulky substituents, even without the
hydrogen bridge donor, are tolerated in the ω-position.6,42
Some of the obtained 1,3-dioxanes potently inhibited cell-free
5-LOX although they were less effective in suppressing 5-LOX
product formation in PMNL than 27a. Together, compound
27a carries an optimized side chain that qualifies for potent 5-
LOX inhibition in cell-free and cell-based assays, thereby
fulfilling the structural requirements for efficient 5-LOX
binding and cellular accumulation.
We concentrated our further efforts on the chromanol
moiety. Molecular docking studies suggest that the chromanol
hydroxyl group is critical for the interaction with 5-LOX.6 In
fact, O-methylation (20, 22) abolished 5-LOX inhibition by
the ω-carboxylic acids 19b and 21, and ring closure as
coumarin (a scaffold found in potent 5-LOX inhibitors62)
under formation of an annulated 2-oxobenzopyran (41) was
also disadvantageous (Tables 1 and 2, Schemes S1 and S2).
Accordingly, replacement of the phenolic alcohol by an
aminocarbonylmethoxy group (32) to increase the distance
between the chromanol core and the hydrogen-bond donor/
acceptor function was associated with a loss of inhibitory
potency. On the other hand, 5-LOX inhibition was slightly
enhanced in the cell-free assay by introducing a free carboxylic
acid group as the O-succinyl ester (31). In activated PMNL, 31
inhibited 5-LOX comparably to 27d, potentially because the
ester in 31 is intracellularly cleaved to the free hydroxyl group
of 27d.
We then investigated whether also oxidative modifications at
the chromanol core lead to potent 5-LOX inhibitors, as yielded
by ω-oxidation of the unsaturated side chain. However, neither
oxidation of the C5 or C7 methyl groups to an aldehyde (3, 4,
7) or carboxylic acid (5) nor additional halogenation (2, 8)
had any improving effect (Table S1, Schemes S1 and S2). The
replacement of the C5 or C7 methyl groups by an aldehyde
(33, 34) or hydroxymethyl moiety (46, 48) was, on the other
hand, compatible with potent 5-LOX inhibition when
Table 2. continued
aIC50 values (μM).
bResidual activities (% control) at 1 μM compound concentration. cResidual activities (% control) at 3 μM compound
concentration. dHighlighted data (gray) are from Pein et al.6 n.d., not determined. eAll values are given as mean ± SEM of single determinations
obtained in 3−4 independent experiments.
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combined with ω-oxidation of the side chain. Motivated by
this finding, we explored a variety of structurally diverse
substituents. Introduction of a methyl ester residue at the C5
methyl group of 13d in combination with methylation of the
13′-carboxylic function was detrimental (25), whereas basic
tertiary amines and N-heterocycles yielded inhibitors of cell-
free 5-LOX that were comparably potent to the nonsubstituted
derivative (for pyrrolidino, 35; for dimethylamino, 23, 36; for
morpholino, 37; or for piperidinyl substitution, 38). An
additional more distant nitrogen atom (N-methyl-piperazinyl,
39) was detrimental, and substitution of both C5 and C7
positions with dialkylated aminomethyl groups (24, 40) was
not tolerated. While substituents at C5 and C7 of chromanol
provide limited options to improve 5-LOX inhibition, all of
these modifications substantially impaired the suppression of
5-LOX product biosynthesis in PMNL (Tables 1 and 2,
Schemes S1 and S2), and we conclude that the natural
chromanol moiety of vitamin E already represents an
evolutionally optimized compromise between potent 5-LOX
inhibition and access to the enzyme in innate immune cells.
The 12a′,13′-dihydroxylated α-tocotrienol 27a combines these
features and was selected as a promising drug candidate for
further pharmacological studies.
Figure 1. Correlation network of the compound library for inhibition of 5-LOX in PMNL. The network visualizes structural similarity between
compounds calculated using Tanimoto similarity. Nodes represent individual compounds, and connecting edges represent Tanimoto coefficients >
0.9. The node shape differentiates between derivatives derived from amplexichromanols (AC), garcinoic acids (GA), or other leads, and the filling
highlights the parental series, i.e., amplexichromanol (red), garcinoic acid (blue), tocopherol, and tocotrienol (green). The node size reflects the
potency (IC50 values) of the compound to inhibit 5-LOX product formation in PMNL. For nodes with dotted lines, IC50 values were not
determined.
Figure 2.Molecular insights into 5-LOX inhibition by 27a. (A) Effect of the arachidonic acid (AA) concentration on 5-LOX inhibition by 27a. (B)
Reversibility of 5-LOX inhibition by 27a. Samples were preincubated with a vehicle or compound for 15 min, 10-fold diluted, and incubated for
another 5 min before AA was added. The number in brackets indicates the diluted compound concentration after preincubation. (C) Effect of
Triton X-100 (0.01%) on 5-LOX inhibition by 27a. (D) Scavenging of DPPH radicals by 27a. (E) Fluorescence excitation spectra as a percentage
of maximum fluorescence intensity (left panel) and spectral center of mass of the fluorescence emission variations (right panel) shown for 5-LOX
titrated with 13d, 27a, or 12a. (F) Effect of 27a on the inhibition of wild-type 5-LOX (wt), the triple mutant Trp13Ala, Trp75Ala, and Trp102Ala
5-LOX (3W), and the single mutant Arg101Asp 5-LOX (R101D). (G) Molecular docking pose of 27a in the allosteric binding site of 5-LOX
showing the interaction with Asp170, Arg138, Glu134, and Glu108. Hydrogen bonds are shown as red (HBA) and green (HBD) arrows and
hydrophobic contacts as yellow spheres. Data are expressed as mean ± SEM (A−D, F) with single values (B) or mean ± SEM (transparent area)
from n = 2 (E), n = 3 (A−C), and n = 4 (D, F) independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs 20 μM AA (A), control (D),
absence of Triton X-100 (C), wt 5-LOX (F), or as indicated (B); two-way ANOVA + Tukey’s post hoc test (A, F), RM one-way ANOVA + Tukey’s
post hoc test (B, D), two-tailed paired t-test of log data (C).
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Figures 1 and S1 summarize the SARs for 5-LOX inhibition
in a network that was calculated based on the structural
similarity of the derivatives, with the size of the symbols
indicating their potency in cell-free (Figure S1) and cell-based
assays (Figure 1).
Mechanism of 5-LOX Inhibition and Binding Mode.
Compound 27a inhibited human recombinant 5-LOX
independent of the substrate concentration (Figure 2A) in a
reversible manner (Figure 2B). Nonspecific inhibition through
detergent-sensitive colloidlike aggregates was excluded by
supplementing the detergent Triton X-100, which did not
substantially impair 5-LOX inhibition by 27a (Figure 2C).
Moreover, the concentrations of 27a that exhibit antioxidative
properties exceed those that effectively inhibit 5-LOX, as
measured by radical scavenging (Figure 2D).
We have recently shown for 13d that it binds 5-LOX close
to Trp102, Trp13, Trp75, and Arg101 at the interface of the
catalytic and regulatory C2-like domain.6 To investigate
whether 27a targets the same site, we monitored the intrinsic
Trp fluorescence of human 5-LOX. The spectral center of mass
was substantially shifted to a shorter wavelength by both 13d
and the endogenous vitamin E metabolite 12a (Figures 2E,
S3A, and S3B), which indicates an altered chemical environ-
ment of Trp following ligand binding.63 This trend was also
evident for 27a, but the wavelength shift was less pronounced
(Figure 2E). We conclude that the 5-LOX binding pose of 27a
is similar but not identical to the ω-carboxylic acids 12a and
13d. Site-directed mutagenesis studies strengthen our hypoth-
esis. The inhibitory activity of 13d is sensitive to Trp102Ala/
Trp13Ala/Trp75Ala triple mutation and Arg101Asp replace-
ment,6 whereas these mutations failed to affect 5-LOX
inhibition by 27a (Figure 2F).
Molecular docking studies confirm results from mutation
experiments and point out poses where 13d interacts with NH
of Trp102 (H-bond with phenolic oxygen) and with Arg101
through an ionic interaction involving the ω-carboxylic acid
function of 13d (Figure S2A). Binding of 27d within the 5-
LOX allosteric site similarly involves an interaction of the
phenol function with Trp102. However, at the tail of the side
chain, the binding with Arg101 of the less polar allylic diol
would be weaker than the one described above for the
carboxylic acid group. Thus, the allylic diol exhibits multiple
stabilizing interactions with various other amino acids, such as
Val110 and Glu134 (Figure S2B). Site-directed mutagenesis
studies showed that the 5-LOX binding affinity of 13d depends
on interactions with Trp102 and Arg101.6 Docking poses for
27a suggest differences in the binding mode compared to the
δ-form 27d (Figures 2G and S2B). Despite the substitution of
the chromanol by three methyl groups, the heterocycle of 27a,
as for 13d and 27d, still lies in the vicinity of Trp102 albeit
with a shift downward. Consequently, the phenol function
does not interact with Trp102 but it exhibits two hydrogen
bonds with Asp170. This result supports the less pronounced
wavelength shift observed in the fluorescence emission spectra
(Figure 2E). Results from the docking studies tend to
demonstrate that interactions of the phenol function are
more efficient than the ones from the diol moiety to anchor
amplexichromanols 27a and 27d in a close range of Trp102.
Eventually, as highlighted by 5-LOX site-directed mutagenesis
experiments (Figure 2F), a direct interaction with Trp102 is
not fully required as long as the ligand strongly interacts with
other spatially close amino acid residues, such as Asp170,
through hydrogen bonds.
5-LOX Inhibition in Innate Immune Cells and Blood.
Compound 27a potently suppressed the biosynthesis of LTB4
and other 5-LOX products (i.e., 5-hydroxyeicosatetraenoic acid
(5-HETE), LTB4 isomers) in PMNL (A23187 plus arach-
idonic acid: IC50 = 0.04 μM; A23187: IC50 = 0.05 μM) (Figure
3A), with superior potency as compared to the cell-free assay
(Table 2). As a reason for this gain in 5-LOX inhibitory
activity, we found that 27a strongly accumulates in PMNL
(Figure 3B), as previously described for the endogenous
vitamin E metabolite 12a, which is enriched in immune cells,
both in vitro and in the inflamed peritoneal cavity in vivo.6 5-
Figure 3. Compound 27a accumulates in innate immune cells and inhibits 5-LOX product formation. (A) Effect of 27a on 5-LOX product
formation (LTB4, its isomers, and 5-H(P)ETE) in PMNL treated with Ca
2+-ionophore A23187 or A23187 and arachidonic acid (AA). (B)
Intracellular uptake of 27a or 12a by PMNL treated with 150 nM of the respective compound for 20 min. Average intracellular concentrations were
calculated for spherical PMNL with a diameter of 13 μm. (C) Effect of 27a or 12a on 5-LOX product formation initiated by A23187 and AA in
LPS-prestimulated monocytes. (D, E) Effect of 27a on AA release from Escherichia coli-stimulated macrophages (D) and fMLP-induced Ca2+ influx
in PMNL (E). (F, G) Effects of 27a or 12a on 5-LOX product formation in human whole blood stimulated with A23187 (F) or LPS and fMLP
(G) upon preincubation with the compounds for 10 min (F, G) or 3 h (F). Data are expressed as mean ± SEM (A, C−G) or mean with single
values (B) from n = 3 (A−E, F, left panel) and n = 4 (F, right panel, G) independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs control
(A, C−G); RM one-way ANOVA + Tukey’s post hoc test (A, C−G).
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LOX product formation in monocytes was instead comparably
suppressed by 12a and 27a (IC50 = 0.5−0.6 μM) (Figure 3C),
despite the higher potency of 27a to inhibit 5-LOX (Tables 1
and 2).
Acute cytotoxic effects were excluded at effective concen-
trations of 27a that inhibit 5-LOX (≤1 μM). Compound 27a
impaired neither mitochondrial dehydrogenase activity in
peripheral blood mononuclear cells (PBMCs) (Figure S4A),
an indicator of cell viability, nor membrane intactness in
monocytes within 2 or 24 h (Figure S4B). At higher
concentrations, 27a induced a rapid release of lactate
dehydrogenase (LDH), which was not evident for the
endogenous vitamin E metabolite 12a (Figure S4B).
Our data point toward a direct inhibition of 5-LOX in
immune cells. On the one hand, the enzyme was potently
inhibited in PMNL by 27a in the presence of exogenous
arachidonic acid (IC50 = 0.04 μM), which uncouples LT
formation from the cPLA2-triggered release of arachidonic acid
and its transfer to 5-LOX by FLAP (Figure 3A). On the other
hand, 27a neither reduced the availability of free arachidonic
acid in E. coli-stimulated macrophages (Figure 3D) nor
influenced intracellular levels of Ca2+, an essential cofactor
for cPLA2α and 5-LOX activation, at submicromolar
concentrations (≤1 μM) (Figure 3E). At higher concen-
trations of 27a (10 μM), Ca2+ influx was substantially reduced,
as previously reported for 13d6 and other ω-carboxylic acids.64
Lipophilic carboxylic acids like 12a are often afflicted with
strong plasma protein binding, leading to a loss of inhibitory
activity in tissues and blood.65 In fact, the dialcohol 27a
suppressed 5-LOX product biosynthesis superior to 12a in
activated human blood, when treated with either A23187
(Figure 3F) or the physiological stimuli LPS and N-formyl-
methionyl-leucyl-phenylalanine (fMLP) (Figure 3G). Togeth-
er, compound 27a targets 5-LOX and potently inhibits LT
biosynthesis in innate immune cells and blood, thereby
surpassing the endogenous vitamin E metabolite 12a.
mPGES-1 as a Subordinate Target within Lipid
Mediator Biosynthesis. LOX, COX, and CYP450 mono-
oxygenases drive the multistep conversion of polyunsaturated
fatty acids into lipid mediators and work in concert with
further metabolic enzymes to regulate inflammation.13,22,66
While some of these enzymes predominantly produce
proinflammatory lipid mediators (e.g., mPGES-1), others
additionally participate in homeostasis (e.g., COX-1, COX-2)
or play important roles in terminating inflammation or
triggering resolution (e.g., soluble epoxide hydrolase (sEH),
15-LOX). At micromolar concentrations (10 μM), compound
27a decreased mPGES-1 activity (Figure 4A). Other enzymes
in lipid mediator biosynthesis were not substantially inhibited:
(i) 12-LOX (Figure 4B) and 15-LOX (Figure 4C) in activated
human PMNL, (ii) COX-1 as the isolated ovine enzyme
(Figure 4D) or within human platelets (Figure 4E), (iii)
human recombinant COX-2 (Figure 4F), or (iv) sEH (Figure
4G). 15-LOX product formation was even increased by a trend
at submicromolar 27a concentrations (Figure 4C). In
summary, compound 27a exhibits superior selectivity to the
Figure 4. Compound 27a moderately inhibits mPGES-1 within eicosanoid and docosanoid biosyntheses. (A−G) Effect of 27a on mPGES-1 in
microsomal preparations of IL-1β-treated A549 cells (A), 12-LOX (B), and 15-LOX product formation (C) in PMNL treated with A23187 and
AA, isolated ovine COX-1 (D), COX-1-dependent 12-HHT formation in platelets (E), human recombinant COX-2 (F), and human recombinant
sEH (G). (H) Quantitative illustration of the lipid mediator network of macrophages (M1) treated with 27a (1 μM) and stimulated with
pathogenic E. coli as compared to the vehicle control. The node size represents the mean concentration in pg, and the color intensity denotes the
fold change for each lipid mediator. AA, arachidonic acid; DHA, docosahexaenoic acid; cys-LTs, cysteinyl-LTs; et-LTB4, LTB4 isomers; EPA,
eicosapentaenoic acid; LX, lipoxine; MaR, maresin; 20-OH-LTB4, 20-hydroxy-LTB4; PD, protectin; Rv, resolvin; TX, thromboxane. Data are
expressed as mean (H) + SEM (A-G) from n = 3 independent experiments. *p < 0.05 vs control; RM one-way ANOVA + Tukey’s post hoc test.
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endogenous vitamin E metabolite 12a,6 with 5-LOX as the
primary and mPGES-1 as the subordinate target.
To investigate the consequences on the lipid mediator
network, we stimulated human macrophages (M1 subtype)
with pathogenic E. coli and performed a comprehensive
metabololipidomics analysis. At concentrations that do not
effectively inhibit mPGES-1 (1 μM), 27a preferentially
suppressed the biosynthesis of 5-LOX-derived products, i.e.,
LTB4, its isomers, 5-HETE, 5,15-diHETE, 5-hydroxyeicosa-
pentaenoic acid (HEPE), and 7-hydroxydocosahexaenoic acid
(HDHA) (Figure 4H). On the other hand, PGE2 levels slightly
increased, which we ascribed to the 5-LOX substrate
arachidonic acid being channeled into PGE2 biosynthesis.
Thus, our data indicate that the impact of 27a on the lipid
mediator profile is mainly determined by 5-LOX inhibition, as
shown for macrophages (Figure 4H) and confirmed in
monocytes (Figure S5).
Superior Metabolic Stability against Side-Chain
Truncation. We studied the hepatic metabolism of 12a and
27a using a human liver-on-chip.6 The biochip resembles a
liver sinusoid and consists of a hepatic and vascular
compartment, which are separated by two porous membranes
that serve as cell scaffolds (Figure 5A). For the hepatic
compartment, we selected HepaRG cells, which are considered
to be the closest to human primary hepatocytes among liver
cell lines, and differentiated them into hepatocyte-like and
biliary-like cells. The endothelial layer mimics the endothelial
lining of the liver sinusoid and consists of human umbilical
vein endothelial cells (HUVECs).
The metabolism of 12a and 27a substantially differs. While
12a is truncated to metabolites with varying side-chain lengths
(Figure 5B), 27a is preferentially conjugated with sulfate or
oxidized at 12a′ or 13′ to the respective ω-carboxylic acid
(Figure 5C). Truncation of the side chain was instead
negligible. Despite being a substrate for hepatic ω-oxidation,
27a did not induce CYP450 enzyme expression in HepaRG
cells, as exemplarily studied for CYP3A4 (Figure 5D).
Next, we investigated the metabolism of 27a after oral
administration in mice. Compound 27a was taken up within 1
h, reaching plasma concentrations (0.03−0.9 μM) that
effectively inhibit 5-LOX in vitro (Figure 5E). We confirmed
that the unsaturated chain of 27a is resistant to degradation
Figure 5. Metabolism of 27a in a human liver-on-chip and in mice. (A) Scheme of the human liver-on-chip model. (B, C) The liver-on-chip was
loaded with compound (1 μM) and incubated for 48 h. Extracted chromatograms (representative of three independent experiments) and
concentrations of 12a and metabolites (B) or 27a and metabolites (C). (D) Effect of 27a and zileuton (zil) on CYP3A4 expression in differentiated
HepaRG cells after treatment for 48 h. Fluorescence images (20× magnification) visualize CYP3A4-expressing (CYP3A4+) and CYP3A4-
nonexpressing cells (CYP3A4−) and are representative of nine (w/o) or three independent experiments. (E) Extracted chromatograms
(representative of eight mice) and concentrations of 27a and metabolites in plasma of mice with acute peritonitis 90 min post 27a administration
(10 mg/kg, p.o.). Data are expressed as mean ± SEM (D) and single values (B, C, E) from n = 3 (B, C, D, 27a, and zil, E, w/o), n = 8 (E, 27a), and
n = 9 (D, w/o) independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs control; two-tailed unpaired t-test of log data (B, C, E), ordinary
one-way ANOVA + Tukey’s post hoc test (D). The nomenclature used for LCMs is explained in Table S2.
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but did not detect sulfate conjugates (Figure 5E). We conclude
that 27a is less susceptible to side-chain degradation than the
endogenous metabolite 12a and speculate about species-
specific differences in 27a sulfation between mice and humans.
Improved Epidermal Homeostasis in Experimental
Atopic Dermatitis. LT levels are substantially increased in
relapsing inflammatory skin lesions in atopic dermatitis, as are
other lipid mediators and cytokines.67 To study the effect of
27a on the inflammatory processes leading to skin dysfunction,
we used reconstructed human epidermis (RHE) and induced
cytokine stress. Interleukin (IL)-8, an indicator of the severity
of inflammation in atopic dermatitis,68 was upregulated (Figure
6A), as was thymic stromal lymphopoietin (TSLP) (Figure
S6A), which is an IL-7-like cytokine that propagates skin
lesions by mediating the recruitment and polarization of Th2-
type CD4+ cells.69 Morphological and functional changes in
the epidermal structure are characterized by spongiosis and the
loss of keratohyalin granules (Figures 6B and S6B). The latter
is associated with a diminished expression of filaggrin, one of
the crucial proteins to maintain skin barrier function.70 Along
these lines, cytokine stress triggers transepidermal water loss
(Figure 6C) and allows the fluorescent dye Lucifer yellow to
pass the stratum corneum (Figures 6D and S6C).
Moreover, the pH increased by trend (Figure 6E), which is
believed to hamper skin barrier homeostasis, thereby
interfering with the innate immune defense in atopic
dermatitis.71 Dexamethasone, used as a control, suppressed
these cytokine-induced responses, as expected.
Compound 27a reduced IL-8 levels (Figure 6A), attenuated
the epidermal disorganization induced by cytokine treatment
(Figures 6B and S6B), and substantially improved skin barrier
functions (Figure 6C, D and S6C). The pH was decreased
even below the basal level (Figure 6E). Thus, compound 27a
limits the inflammatory reaction and supports epidermal
homeostasis in experimental atopic dermatitis. On the other
hand, 27a did not influence TSLP expression in the RHE
(Figure S6A), rather excluding a major impact on Th2-
mediated tissue damage. Cytotoxic effects of 27a on human
keratinocytes were excluded under our experimental con-
ditions (Figure S6D).
Attenuated Inflammation in Murine Peritonitis. The
anti-inflammatory efficacy of 27a was investigated for
zymosan-induced murine peritonitis in vivo, which represents
a model of acute inflammation that relies on LTs and other
lipid mediators (Figure 7A).72 During the onset of
inflammation, zymosan activates resident peritoneal macro-
phages that produce LTC4. This cysteinyl-LT increases
vasopermeability in postcapillary venules. Compound 27a,
given i.p., strongly decreased LTC4 levels in the exudate
(Figure 7B) and consequently reduced vascular permeability
(Figure 7C). The progressive phase of inflammation is instead
dominated by infiltrated neutrophils that generate the potent
chemoattractant LTB4. Compound 27a was also active at this
stage and substantially lowered LTB4 levels, both in the
exudate (Figure 7D) and by trend in plasma (Figure S7A). The
influx of cells into the peritoneal cavity (Figure 7E), which is
dominated by neutrophil infiltration,72 was accordingly
reduced.
While oral administration of 27a yielded plasma concen-
trations between 0.02 and 2.58 μM (Figure 7F), concen-
Figure 6. Compound 27a relieves inflammation in reconstructed human epidermis (RHE). RHE exposed to 27a or dexamethasone (dex) was
treated with a cytokine cocktail for 4 days to trigger the inflammatory reaction. (A) Concentration of IL-8 in the growth medium. The dotted line
indicates basal levels without cytokine stress. (B) Morphological changes visualized by hematoxylin and eosin staining (scale bar is 50 μm;
representative of three independent experiments). (C) Transepidermal water loss (TEWL) at the RHE surface. (D) Impermeability of the stratum
corneum. The stratum corneum of cytokine-stressed RHE becomes permeable for Lucifer yellow (green) that diffuses into the viable cell layers, as
shown in the insets in higher magnification (scale bar for the outer box is 20 μm, and scale bar for the inset is 10 μm; representative of three
independent experiments). Nuclei were stained with 4′,6′-diamidino-2-phenylindole (DAPI, blue). (E) pH value at the RHE surface. Data are
expressed as mean ± SEM (A, 27a) with single values (A, dex, C) or mean + floating bars from minimum to maximum values (E) from n = 2 (A)
and n = 3 (C, E) independent experiments. Ordinary one-way ANOVA + Tukey’s post hoc test.
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trations of 27a in the peritoneal exudate were considerably
lower (0.5−4 nM) (Figure 7G) but likely still in a range that
inhibits 5-LOX, given the strong intracellular accumulation of
27a in immune cells in vitro (Figure 3B). Cysteinyl-LTs were
decreased to a basal level by 27a at a dose of 3 mg/kg (Figure
7H). The clinically used 5-LOX inhibitor zileuton (at 3 mg/
kg) did not evoke a stronger effect. Metabololipidomics
profiling showed a preferential drop of arachidonic acid-
derived 5-LOX products in exudates from 27a-treated mice
and a moderate reduction of various other LOX-derived
metabolites (Figure 7I). The latter likely depends on the
reduced availability of free polyunsaturated fatty acids.
Conclusively, 27a is an orally active 5-LOX inhibitor that
potently suppresses LT formation and associated peritoneal
inflammation in vivo.
We have recently shown that the endogenous metabolite
12a augments the systemic concentration of resolvin E3, a
specialized proresolving lipid mediator that actively terminates
the resolution of inflammation.6,22 Although our study focused
on acute inflammation and has only limited predictive power
for the resolution phase, we found resolvin E3 levels already
being moderately increased by 27a at 30 min post zymosan
injection in individual mice (Figure S7B). It is tempting to
speculate that 27a shares the putative proresolving potential of
the endogenous lead compound.
Diminished Airway Hyperreactivity in Experimental
Asthma. Since LTs play a pivotal role in the pathogenesis of
asthma by propagating lung inflammation, immune cell
infiltration, and bronchoconstriction,15,73 we investigated the
effects of 27a in an experimental model of asthma. Mice were
treated with 27a p.o. 60 min before being sensitized with
ovalbumin on days 0 and 7 and monitored up to 21 days
(Figure 8A). Systemic concentrations of 27a peaked at the
days after administration (days 1 and 8) and then rapidly
declined again in the plasma and lung (Figure 8B). Gavage of
27a lowered lung levels of LTB4 and its isomers (Figure 8C),
blocked ovalbumin-induced bronchial hyperreactivity to
carbachol (Figure 8D), and fully restored the adrenergic
bronchial relaxation induced by salbutamol (Figure 8E).
Together, compound 27a is orally available and distributed
to the lung, thereby effectively suppressing pulmonary LT
levels and asthmatic airway contraction.
■ DISCUSSION AND CONCLUSIONS
Inspired by the endogenous vitamin E metabolite 12a, which
may mediate immunomodulatory effects of vitamin E,6,7 we
designed a novel class of potent 5-LOX inhibitors that limit
inflammation. We previously explored 13′-garcinamides, which
impress through their potent 5-LOX inhibitory activity,42 but
were substantially less active in innate immune cells. Extended
SAR studies revealed oxidative ω-modifications of the side
Figure 7. Compound 27a inhibits 5-LOX product formation and limits inflammation in murine peritonitis. (A) Time scale for zymosan-induced
murine peritonitis. (A−I) Mice received 27a (B−E, I: 10 mg/kg; F, G: 30 mg/kg; H: 3 mg/kg; B−E: i.p.; F−I: p.o.) or zileuton (zil; B−E: 10 mg/
kg; F, G: 30 mg/kg; H: 3 mg/kg; B−E: i.p.; F−H: p.o.) and were killed 30 min (B, C, F−I) or 4 h (D, E) post zymosan injection. (B, H) LTC4
levels in the exudate analyzed by ELISA. (C) Vascular permeability. (D) LTB4 levels in the exudate analyzed by ELISA. (E) Immune cell
infiltration into the peritoneal cavity. (F, G) Concentration of 27a in the plasma (F) and exudate (G). (I) Quantitative illustration of the lipid
mediator network in the peritoneal exudate from mice given 27a as compared to the vehicle. The node size represents the mean concentration in
pg, and the color intensity denotes the fold change for each lipid mediator. °LTC4 was analyzed by ELISA, and all other lipid mediators and fatty
acids were analyzed by UPLC-MS/MS. AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LX, lipoxin; MaR, maresin;
20-OH-LTB4, 20-hydroxy-LTB4; PD, protectin; Rv, resolvin; t-LTB4, LTB4 isomer; TX, thromboxane. Data are expressed as mean (I) with single
values (B−H) from n = 3 (F, w/o), n = 4 (C, 27a), n = 5 (C, w/o, F, 27a), n = 6 (B, C, zil, D, E), n = 8 (H, w/o), n = 9 (G, w/o, H, zil, I, w/o),
and n = 10 (F, zil, G, 27a and zil, H, 27a, I, 27a) mice. Two-tailed unpaired t-test of log data (B−H).
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chain as a superior strategy toward potent 5-LOX inhibitors
that maintain their privileged access to innate immune cells.
These two criteria were best realized by the C12a′-/C13′-
dihydroxylated α-tocotrienol 27a, which inhibits 5-LOX in a
substrate-independent manner at concentrations that do not
allow efficient radical scavenging. Compound 27a seems to
bind 5-LOX slightly displaced from 12a and 13d in the vicinity
of Trp102, as suggested by molecular docking studies, Trp
fluorescence spectroscopy, and site-directed mutagenesis. In
contrast to ω-oxidation, the chromanol core and the
unsaturated side chain of 27a offer little space for structural
optimization. Although we identified modifications that turn
27a in an even more potent 5-LOX inhibitor, the
pharmacologically relevant inhibition of 5-LOX product
formation in PMNL was not enhanced.
Compound 27a strongly accumulates in PMNL, reaching a
comparable intracellular concentration as 12a. Accordingly,
27a superiorly inhibits 5-LOX product biosynthesis in
activated PMNL and human blood but not in monocytes.
These cell-type-specific differences are in favor of our
hypothesis that LCMs are efficiently taken up by cells through
specific transport systems. Within cellular lipid mediator
biosynthesis, 5-LOX is the direct and primary target of 27a,
and its inhibition shapes the lipid mediator profile of activated
human macrophages and monocytes. Although 27a is
considerably more selective than 12a,6 both compounds
additionally inhibit mPGES-1 at high concentrations, which
might be beneficial to damp the redirection of the 5-LOX
substrate arachidonic acid toward proinflammatory PGE2
biosynthesis.
Compound 27a is orally available and reaches plasma and
lung concentrations that effectively inhibit 5-LOX in vitro.
Rapid clearance of 27a from the plasma is accompanied by
substantial retardation in tissues, including inflamed lungs.
Along these lines, 27a is more stable against side-chain
truncation than 12a. While we did not detect 27a metabolites
in mice in vivo (within 90 min), 27a was efficiently sulfated or
ω-oxidized to a carboxylic acid in a human liver-on-chip
(within 48 h), which might be related to the kinetics or
species-specific differences in 27a metabolism. It is tempting to
speculate that both metabolites of 27a, the sulfate and ω-
carboxylic acid, possess 5-LOX inhibitory activity or, in the
case of the 27a sulfate, might be hydrolyzed to the active
compound in tissues that highly express sulfatases, such as the
lung and liver.74
We demonstrate anti-inflammatory efficacy of 27a in murine
models of peritonitis and asthma in vivo, for both i.p. and p.o.
administration, and in experimental atopic dermatitis in vitro
using RHE. Compound 27a effectively suppresses LT levels
along with LT-driven hallmarks of inflammation, i.e., immune
cell infiltration, vasopermeability, and bronchial hyperreactiv-
ity.
In conclusion, we here present compound 27a, a potent and
orally active LCM-inspired 5-LOX inhibitor that shares the
favorable pharmacological profile of the endogenous vitamin E
metabolite 12a but is even more potent, selective, and
metabolically stable, thereby allowing an efficient suppression
of inflammation in vitro and in vivo. Whether 27a shares the
proposed proresolving activities of 12a needs further
investigation.
■ EXPERIMENTAL SECTION
Isolation and Semisynthesis of Vitamin E Derivatives. 1H
and 13C NMR along with 2D NMR data were obtained on a Bruker
Avance DRX 500 MHz spectrometer (500 and 125 MHz,
respectively; BRUKER, Bremen, Germany) or a JEOL JNM-ECZS
400 MHz spectrometer (400 and 100 MHz, respectively; JEOL Ltd.,
Akishima, Tokyo, Japan) in deuterated chloroform, methanol, or
acetone and calibrated using the residual undeuterated solvent
resonance as an internal reference. IR spectra were recorded on a
Thermo Scientific Nicolet iS5 FT-IR spectrometer (Thermo
Scientific). Mass spectrometry analyses were performed on a JEOL
JMS-700 (JEOL Ltd.) double-focusing mass spectrometer with
reversed geometry, equipped with a pneumatically assisted EI or
FAB source and on a BRUKER ESQUIRE 3000+ spectrometer
(BRUKER) for ESI analyses in both positive and negative modes.
Chromatographic analysis was performed on a Prominence-i LC-
2030C (Shimadzu, Noisiel, France) equipped with a refrigerated
autosampler and a column oven. The HPLC system was coupled to
an evaporative light-scattering detector (ELSD SEDEX 90 LT,
SEDERE). Then, 5 μL samples refrigerated at 10 °C were injected
onto a Phenomenex Luna C18 column (150 mm × 4.6 mm, 5 μm)
heated at 20 °C. A gradient of water with 0.1% formic acid (A) and
acetonitrile with 0.1% formic acid (B) was applied (65% B for 1 min,
65−77% B within 4 min, 77% B for 8 min, 77−100% B within 5 min,
100% B for 6 min) at a flow rate of 1 mL/min. ELSD experiments
were performed at 50 °C, and nitrogen was used as the nebulization
gas (3.5 bar). Data were acquired and processed with LabSolutions
Software (Shimadzu, Noisiel, France). Spectra for selected vitamin E
analogues (13a, 13d, 27a, 27d) are shown in Figures S57−S60. Purity
determined using ELSD experiments was ≥95%. Chromatographic
Figure 8. Compound 27a suppresses bronchial hyperreactivity and
pulmonary LT formation in mice sensitized to ovalbumin. (A) Time
scale for the experimental asthma model. (B−E) Compound 27a (10
mg/kg) was p.o. administered to mice prior to injection of ovalbumin
(OVA) on days 0 and 7. (B) Concentrations of 27a in plasma (nM)
and lung (pmol/g lung tissue). (C) Pulmonary levels of LTB4 and its
isomers on day 3 in pg/mg lung tissue. (D, E) Bronchial reactivity to
carbachol (D) or salbutamol (E) on day 21. Data are expressed as
mean with single values (C) or mean ± SEM (B, D, E) from n = 5 (B,
days 1−10, C), n = 6 (B, day 21), n = 7 (E, OVA, OVA + 27a), n = 8
(D, OVA + 27a), n = 11 (D, OVA, E, control), and n = 12 (D,
control) mice. ns, not significant; ***p < 0.001 vs control or as
indicated; two-tailed unpaired t-test of log data (C), two-way ANOVA
+ Bonferroni’s post hoc test (B, D, E).
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separations, such as flash chromatography, were performed on
IntelliFlash 310 (Analogix) using a silica gel column Chromabond
flash RS column (Macherey-Nagel). Reactions under microwave
irradiations were performed using an Anton Paar Monowave 300
microwave reactor (Anton Paar). All reactions under microwave
irradiations were performed using the stirring option in borosilicate
glass vials of 10 or 30 mL (G10 or G30) sealed with PTFE-coated
silicone septa (at the end of the irradiation, cooling of reaction
mixtures was realized by compressed air). The microwave instrument
consists of a continuous focused microwave power output from 0 to
600 W. The target temperature was reached with a ramp of 3 min, and
the chosen microwave power was maintained at a constant to hold the
mixture at this temperature. The reaction temperature was monitored
using a calibrated infrared sensor, and the reaction time included the
ramp period. The microwave irradiation parameters (power, temper-
ature, and time) were monitored by the Monowave software package.
(R)-2-((3E,7E,11Z)-13-Hydroxy-4,8,12-trimethyltrideca-3,7,11-
trien-1-yl)-2,8-dimethylchroman-6-yl-4-methylbenzenesulfonate
(49). To a solution of δ-(Z)-deoxyamplexichromanol 10e (152 mg,
0.36 mmol, 1 equiv) in dichloromethane (5 mL) were added 4-
toluenesulfonyl chloride (75 mg, 0.39 mmol, 1.1 equiv) and
triethylamine (60 μL, 0.43 mmol, 1.2 equiv). The reaction mixture
was stirred at room temperature for 2.5 h. Then, the reaction was
quenched with a saturated aqueous solution of sodium bicarbonate.
The resulting mixture was extracted three times with diethyl ether.
The combined organic layers were washed with water and brine, dried
over anhydrous sodium sulfate, filtered, and concentrated under
reduced pressure. The residue was purified by column chromatog-
raphy on silica gel eluted with a petroleum ether/diethyl ether mixture
6:4 to afford the desired product 49 with 72% yield. Brown oil; Rf =
0.62 (petroleum ether/acetone/dichloromethane 7:2:1). 1H NMR
(400 MHz, CDCl3) δH 7.71 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 7.9 Hz,
2H), 6.55 (d, J = 2.6 Hz, 1H), 6.53 (d, J = 2.4 Hz, 1H), 5.26 (t, J = 7.4
Hz, 1H), 5.14−5.07 (m, 2H), 4.09 (s, 2H), 2.67−2.63 (m, 2H), 2.44
(s, 3H), 2.15-2.04 (m, 6H), 2.05 (s, 3H), 1.99−1.95 (m, 4H), 1.81−
1.69 (m, 2H), 1.78 (s, 3H), 1.65−1.50 (m, 2H), 1.58 (s, 6H), 1.25 (s,
3H). 13C NMR (100 MHz, CDCl3) δC 150.7, 145.0, 141.5, 135.3,
134.6, 134.5, 132.9, 129.6 (2C), 128.6 (2C), 128.2, 127.5, 124.8,
124.2, 121.9, 121.2, 120.2, 76.2, 61.6, 39.9 (2C), 39.7, 30.9, 26.6, 26.3,
24.1, 22.4, 22.2, 21.8, 21.3, 16.1 (2C), 15.9.
(2Z,6E,10E)-13-((R)-2,8-Dimethyl-6-(tosyloxy)chroman-2-yl)-
2,6,10-trimethyltrideca-2,6,10-trienoic Acid (50). To a solution of
49 (152 mg, 0.27 mmol, 1 equiv) in a mixture of 1:9 dimethyl
sulfoxide/dichloromethane (5 mL) was added 2-iodoxybenzoic acid
(280 mg, 0.54 mmol, 2 equiv). The reaction mixture was stirred at
room temperature for 12 h. Then, the reaction was quenched with a
saturated aqueous solution of sodium bicarbonate. The resulting
mixture was extracted three times with dichloromethane. The
combined organic layers were washed with water and brine, dried
over anhydrous sodium sulfate, filtered, and concentrated under
reduced pressure. The crude aldehyde was used for the next step
without further purification. To a solution of aldehyde (145 mg, 0.26
mmol, 1 equiv) in 1,4-dioxane (5 mL) at 0 °C were added sulfamic
acid (40 mg, 0.42 mmol, 1.6 equiv), 2-methyl-2-butene (1.7 mL, 13
mmol, 50 equiv), and a solution of sodium chlorite (33 mg, 0.36
mmol, 1.4 equiv) in water (1.8 mL). The reaction mixture was stirred
at 0 °C for 2 h. Then, the reaction was quenched with sodium sulfite
and diluted with water. The resulting mixture was extracted three
times with diethyl ether. The combined organic layers were washed
with water and brine, dried over anhydrous sodium sulfate, filtered,
and concentrated under reduced pressure. The residue was purified by
column chromatography on silica gel using a 7:3 mixture of petroleum
ether/diethyl ether as the eluent to afford the expected product 50
with 75% yield over the two-step oxidation. Brown oil; Rf = 0.45
(petroleum ether/ethyl acetate 75:25). 1H NMR (400 MHz, CDCl3)
δH 7.72 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 6.55 (d, J = 2.6
Hz, 1H), 6.52 (d, J = 2.8 Hz, 1H), 6.05 (td, J = 1.4, 7.9 Hz, 1H),
5.13−5.10 (m, 2H), 2.67−2.58 (m, 4H), 2.45 (s, 3H), 2.12−2.04 (m,
6H), 2.05 (s, 3H), 1.98−1.94 (m, 2H), 1.90 (s, 3H), 1.83−1.69 (m,
2H), 1.64−1.50 (m, 2H), 1.58 (s, 6H), 1.25 (s, 3H). 13C NMR (100
MHz, CDCl3) δC 171.1, 150.8, 145.1, 141.5, 135.4, 134.8 (2C), 132.9,
129.7 (2C), 128.7 (2C), 127.6, 126.3, 124.5, 124.2, 122.0, 121.2,
120.3, 76.3, 39.9, 39.8, 39.4, 31.0, 26.7, 26.4, 24.2, 22.4, 22.2, 21.9,
16.2, 16.1, 16.0, 13.8. IR (ATR) νmax 2923, 2852, 1686, 1473, 1454,




2,6,10-trimethyltrideca-2,6,10-trienoic Acid (13e). To a solution of
50 (141 mg, 0.24 mmol, 1 equiv) in methanol (8 mL) was added
sodium hydroxide (16 mmol, 640 mg). The mixture was stirred at 70
°C for 3 h. Then, the reaction was quenched with an aqueous solution
of hydrochloric acid (1 M). The resulting mixture was extracted three
times with dichloromethane. The combined organic layers were
washed with water and brine, dried over anhydrous sodium sulfate,
filtered, and concentrated under reduced pressure. The residue was
purified by column chromatography eluted with a petroleum ether/
acetone mixture, 8:2, to afford the desired product 13e with 95%
yield. Pale-yellow oil; Rf = 0.29 (petroleum ether/acetone 8:2).
1H
NMR (400 MHz, CDCl3) δH 6.47 (d, J = 3.5 Hz, 1H), 6.38 (d, J = 2.8
Hz, 1H), 6.24 (bs, 1H), 6.06 (td, J = 1.4, 7.2 Hz, 1H), 5.14−5.09 (m,
2H), 2.69 (t, J = 6.8 Hz, 2H), 2.60 (dd, J = 7.3, 13.7 Hz, 2H), 2.19−
2.16 (m, 2H), 2.13−2.10 (m, 2H), 2.12 (s, 3H), 2.09−2.04 (m, 6H),
1.98−1.95 (m, 2H), 1.90 (s, 3H), 1.83−1.71 (m, 2H), 1.67−1.49 (m,
2H), 1.58 (s, 3H), 1.57 (s, 3H), 1.26 (s, 3H). 13C NMR (100 MHz,
CDCl3) δC 172.3, 147.8, 146.4, 146.1, 135.2, 134.2, 127.5, 126.0,
125.1, 124.5, 121.4, 115.8, 112.7, 75.5, 39.7, 39.6, 39.1, 31.5, 28.3,
26.7, 24.2, 22.6, 22.3, 20.7, 16.2, 16.0 (2C). IR (ATR) νmax 3335,
2924, 2852, 1686, 1471, 1378, 1220, 1095, 939 cm−1. HRMS (EI) m/
z calcd for C27H38O4 [M
+•] 426.2770, found 426.2768.
(R)-5-Chloro-2,8-dimethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-
chroman-6-ol (51). To a solution of 1d (1 g, 2.5 mmol, 1 equiv) in
methanol (15 mL) was added N-chlorosuccinimide (400 mg, 1.2
equiv). The reaction was stirred at room temperature for 2 h until
completion monitored by TLC (petroleum ether/acetone 8:2). After
removal of the solvent under reduced pressure, the crude residue was
taken into hexane and filtered on a Celite pad. The filtrate was
concentrated under reduced pressure and purified on silica gel flash
chromatography using a 95:5 mixture of petroleum ether/acetone as
the mobile phase, leading to 5-chloro-δ-tocopherol 51 with 95% yield.
Pale-yellow oil. Rf = 0.74 (petroleum ether/acetone 8:2).
1H NMR
(400 MHz, CDCl3) δH 6.70 (d, J = 0.7 Hz, 1H), 5.04 (s, 1 H, OH),
2.71 (q, J = 6.7 Hz, 2H), 2.12 (d, J = 0.7 Hz, 3H), 1.86−1.72 (m,
2H), 1.54−1.47 (m, 4H), 1.44−1.32 (m, 4H), 1.31−1.17 (m, 11H),
1.15−1.00 (m, 5H), 0.88−0.82 (m, 12H). 13C NMR (100 MHz,
CDCl3) δC 146.2, 143.9, 126.2, 118.8, 116.5, 115.3, 75.5, 39.6, 39.5,
37.6, 37.5, 37.4, 32.9, 32.8, 31.0, 29.8, 28.1, 24.9, 24.6, 23.9, 22.9,
22.8, 21.4, 21.1, 19.9, 19.8, 16.1. HRMS (ESI) m/z calcd for
C27H44ClO2 [M − H]− 435.3030, found 435.3033.
(R)-5-Chloro-6-hydroxy-2,8-dimethyl-2-((4R,8R)-4,8,12-
trimethyltridecyl)chromane-7-carbaldehyde (2). To a stirred
solution of 51 (500 mg, 1.14 mmol) in dry THF (20 mL) were
added magnesium chloride (1.085 g, 10 equiv), paraformaldehyde
(1.094 g, 32 equiv), and triethylamine (4.8 mL, 32 equiv) at room
temperature. The mixture was stirred under reflux until the
completion of the reaction was observed by TLC. The heterogeneous
mixture was cooled down to room temperature, and 1 N HCl (10
mL) and Et2O (30 mL) were added dropwise. The organic layer was
separated, and the aqueous layer was extracted with Et2O (2 × 10
mL). The combined organic extracts were washed with brine (20
mL), dried over Na2SO4, and evaporated to dryness. Purification by
column chromatography on silica gel, using a petroleum ether/diethyl
ether (PE/Et2O) mixture as the mobile phase (100:0 to 95:5),
afforded the desired formylated product 2 with 75% yield. Rf = 0.50
(Et2O/petroleum ether 1:9).
1H NMR (500 MHz, acetone-d6) δH
12.02 (s, 1H), 10.39 (s, 1H), 2.82−2.85 (m, 2H), 2.49 (s, 3H), 1.85−
1.95 (m, 2H), 1.29 (s, 3H), 1.05−1.66 (m, 21H), 0.85−0.88 (m,
12H). 13C NMR (125 MHz, acetone-d6) δC 197.2, 153.3, 145.6,
131.4, 128.6, 118.8, 118.5, 76.9, 40.1, 39.9, 38.0 (2C), 38.1 (2C),
33.5, 33.3, 31.1, 28.7, 25.5, 25.1, 22.8, 24.0, 23.0, 22.9, 21.6, 20.0,
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trimethyltridecyl)chromane-5-carbaldehyde (4). To a solution of
aldehyde 338 (66 mg, 0,16 mmol, 1.0 equiv) in 3 mL of distilled THF
at −5 °C under a nitrogen atmosphere was added dropwise n-BuLi
1.6 M in hexane (200 μL, 0.30 mmol, 1.95 equiv). The reaction
mixture was stirred for 2 h at −5 °C. Then, bromomethyl methyl
ether (30 μL, 0.37 mmol, 2.4 equiv) was added, and the resulting
mixture was stirred for 20 min. After dilution with EtOAc (15 mL),
the organic layer was washed with a saturated aqueous NH4Cl
solution, water, and brine (15 mL each), dried over sodium sulfate,
and filtered. The solvent was evaporated under reduced pressure. The
crude product was purified by preparative TLC using an 8:2 mixture
of ether/petroleum ether to lead to 58 mg of 4 (80% yield). Rf = 0.30
(Et2O/petroleum ether 1:9).
1H NMR (500 MHz, acetone-d6) δH
10.57 (s, 1H), 7.00 (s, 1H), 5.25 (s, 2H), 3.48 (s, 3H), 3.01−3.11 (m,
2H), 2.19 (s, 3H), 1.72−1.82 (m, 2H), 1.26 (s, 3H), 1.09−1.59 (m,
21H), 0.85−0.88 (m, 12H). 13C NMR (125 MHz, acetone-d6) δC
191.8, 155.6, 147.8, 135.4, 123.0, 122.6, 117.0, 96.0, 76.0, 56.0, 40.2,
40.1, 38.1 (2C), 38.0 (2C), 33.5, 33.3, 31.6, 28.7, 25.5, 25.1, 24.1,
23.0, 22.9, 22.0, 21.6, 20.1, 20.0, 17.4. HRMS (FAB) m/z calcd for
C30H50O4 [M
+•] 474.3704, found 474.3706.
(2E,6E,10E)-Methyl-13-((R)-6-methoxy-2,8-dimethylchroman-2-
yl)-2,6,10-trimethyltrideca-2,6,10-trienoate (53). To a solution of
sodium hydride (140 mg, 3.5 mmol, 5 equiv) in dimethyformamide
(5 mL) were added at 0 °C a solution of 13d (300 mg, 0.70 mmol, 1
equiv) in dimethyformamide (5 mL) and iodomethane (174 μL, 2.8
mmol, 4 equiv). After 15 min at 0 °C, the reaction was stirred at room
temperature for 1 h. Then, the reaction was quenched with water. The
resulting mixture was extracted three times with diethyl ether. The
combined organic layers were washed with water and brine, dried over
anhydrous sodium sulfate, filtered, and concentrated under reduced
pressure. The residue was purified by column chromatography on
silica gel eluted with a petroleum ether/acetone (98:2) mixture to
afford 53 with 67% yield. Yellow oil; Rf = 0.76 (petroleum ether/
acetone 9:1). 1H NMR (400 MHz, CDCl3) δH 6.74 (td, J = 1.4, 7.3
Hz, 1H), 6.56 (d, J = 2.7 Hz, 1H), 6.44 (d, J = 3.0 Hz, 1H), 5.15−
5.12 (m, 2H), 3.73 (s, 6H), 2.75−2.71 (m, 2H), 2.26 (dd, J = 7.5,
15.0 Hz, 2H), 2.15 (s, 3H), 2.13−2.04 (m, 6H), 1.99−1.95 (m, 2H),
1.83 (s, 3H), 1.81−1.71 (m, 2H), 1.68−1.51 (m, 2H), 1.59 (s, 6H),
1.26 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 168.8, 152.2, 146.2,
142.5, 135.1, 134.0, 127.5, 127.4, 125.2, 124.5, 121.0, 114.9, 111.1,
75.4, 55.8, 51.8, 39.8, 39.7, 38.3, 31.5, 27.5, 26.7, 24.2, 22.8, 22.3,
16.4, 16.1, 16.0, 12.6. IR (ATR) νmax 2924, 2849, 1713, 1481, 1435,
1274, 1219, 1192, 1150, 1122, 1094, 1060 cm−1. MS (EI) m/z calcd
for C29H42O4 [M
+•] 454.3, found 454.4.
(6E,10E)-Methyl-13-((R)-6-hydroxy-2,8-dimethylchroman-2-yl)-
2,6,10-trimethyltrideca-6,10-dienoate (21). To a solution of methyl
δ-garcinoate 526 (110 mg, 0.25 mmol, 1 equiv) in dry methanol (10
mL), magnesium turnings were added (122 mg, 5 mmol, 20 equiv).
The reaction mixture was stirred at room temperature for 16 h. Then,
the reaction was quenched with water. The resulting mixture was
extracted 3 times with diethyl ether. The combined organic layers
were washed successively with water and brine, dried over anhydrous
sodium sulfate, filtered, and concentrated under reduced pressure.
The crude residue was purified by column chromatography on silica
gel eluted with a petroleum ether/acetone (95:5) mixture to afford
the desired reduced product 21 with 66% yield. Brown oil; Rf = 0.45
(petroleum ether/acetone/dichloromethane 7:2:1). 1H NMR (400
MHz, CDCl3) δH 6.48 (d, J = 3.0 Hz, 1H), 6.39 (d, J = 3.0 Hz, 1H),
5.14−5.06 (m, 2H), 3.67 (s, 3H), 2.69 (t, J = 6.9 Hz, 2H), 2.44 (dd, J
= 7.0, 13.0 Hz, 1H), 2.12 (s, 3H), 2.09−2.02 (m, 4H), 1.98−1.92 (m,
4H), 1.81−1.71 (m, 2H), 1.67−1.49 (m, 4H), 1.58 (s, 3H), 1.55 (s,
3H), 1.39−1.33 (m, 2H), 1.26 (s, 3H), 1.14 (d, J = 7.0 Hz, 3H). 13C
NMR (100 MHz, CDCl3) δC 177.7, 148.0, 146.0, 135.2, 134.8, 127.4,
124.6, 124.4, 121.3, 115.8, 112.7, 75.4, 51.7, 39.8, 39.6, 39.5 (2C),
33.4, 31.5, 26.6, 25.6, 24.2, 22.6, 22.3, 17.2, 16.2, 16.0, 15.9. IR (ATR)
νmax 2926, 2854, 1735, 1714, 1464, 1218, 1159, 854 cm
−1. HRMS
(FAB) m/z calcd for C28H42O4 [M
+•] 442.3083, found 442.3078.
(6E,10E)-Methyl-13-((R)-6-methoxy-2,8-dimethylchroman-2-yl)-
2,6,10-trimethyltrideca-6,10-dienoate (22). 22 was obtained from
53 with 72% yield using the same method as described above for 21.
Brown oil; Rf = 0.68 (petroleum ether/acetone/dichloromethane
7:2:1). 1H NMR (400 MHz, CDCl3) δH 6.56 (d, J = 2.9 Hz, 1H),
6.44 (d, J = 2.9 Hz, 1H), 5.13 (td, J = 1.1 Hz, 7.1 Hz, 1H), 5.08 (td, J
= 1.2 Hz, 6.9 Hz, 1H), 3.73 (s, 3H), 3.66 (s, 3H), 2.75−2.71 (m, 2H),
2.48−2.39 (m, 1H), 2.15 (s, 3H), 2.13−2.03 (m, 6H), 1.98−1.93 (m,
4H), 1.85−1.71 (m, 2H), 1.68−1.51 (m, 2H), 1.59 (s, 3H), 1.55 (s,
3H), 1.41−1.34 (m, 2H), 1.26 (s, 3H), 1.14 (d, J = 7.0 Hz, 3H). 13C
NMR (100 MHz, CDCl3) δC 177.5, 152.2, 146.2, 135.2, 134.8, 127.4,
124.6, 124.4, 121.0, 114.8, 111.1, 75.4, 55.8, 51.6, 39.8, 39.5 (2C),
33.4, 31.5, 29.8, 26.7, 25.6, 24.2, 22.8, 22.3, 17.2, 16.3, 16.0, 15.9. IR
(ATR) νmax 2923, 2853, 1738, 1481, 1463, 1377, 1219, 1196, 1151,




trimethyltrideca-6,10-dienoic Acid (19b). To a solution of 21 (60
mg, 1 equiv) in methanol, crushed sodium hydroxide (2 M) was
added. The mixture was stirred at 70 °C for 4 h, and then, the
reaction was quenched with an aqueous solution of hydrochloric acid
(1 M). The resulting mixture was extracted three times with diethyl
ether, and the combined organic layers were washed with water and
brine, dried over anhydrous sodium sulfate, filtered, and concentrated
under reduced pressure. The residue was purified by column
chromatography on silica gel eluted with a petroleum ether/acetone
(8:2) mixture to afford the corresponding carboxylic acid 19b with
61% yield from 13d (3 steps). Brown oil; Rf = 0.26 (petroleum ether/
acetone/dichloromethane 7:2:1). 1H NMR (400 MHz, CDCl3) δH
6.48 (d, J = 3.0 Hz, 1H), 6.38 (d, J = 2.9 Hz, 1H), 5.14−5.10 (m,
2H), 2.69 (t, J = 6.8 Hz, 2H), 2.48−2.43 (m, 1H), 2.12 (s, 3H),
2.10−2.03 (m, 4H), 1.99−1.94 (m, 4H), 1.83−1.71 (m, 2H), 1.67−
1.50 (m, 4H), 1.59 (s, 3H), 1.56 (s, 3H), 1.45−1.36 (m, 2H), 1.26 (s,
3H), 1.17 (d, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δC
182.9, 147.8, 146.1, 135.2, 134.7, 127.5, 124.6, 124.5, 121.4, 115.8,
112.7, 75.5, 39.8, 39.6, 39.5, 39.3, 33.2, 31.4, 26.6, 25.4, 24.2, 22.6,
22.3, 17.0, 16.2, 16.0, 15.9. IR (ATR) νmax 2927, 1703, 1609, 1465,
1378, 1219, 1097, 853, 737 cm−1. HRMS (FAB) m/z calcd for
C27H40O4 [M
+•] 428.2927, found 428.2930.
(6E,10E)-13-((R)-6-Methoxy-2,8-dimethylchroman-2-yl)-2,6,10-
trimethyltrideca-6,10-dienoic Acid (20). 20 was obtained from 22
with 42% yield from 13d (3 steps) using the same method as
described above for 19b. Brown oil; Rf = 0.55 (petroleum ether/
acetone/dichloromethane 7:2:1). 1H NMR (400 MHz, CDCl3) δH
6.57 (d, J = 2.8 Hz, 1H), 6.44 (d, J = 3.0 Hz, 1H), 5.15−5.08 (m,
2H), 3.73 (s, 3H), 2.75−2.71 (m, 2H), 2.48−2.43 (m, 1H), 2.16 (s,
3H), 2.13−2.04 (m, 6H), 1.99−1.95 (m, 4H), 1.85−1.72 (m, 2H),
1.68−1.51 (m, 2H), 1.59 (s, 3H), 1.57 (s, 3H), 1.46−1.36 (m, 2H),
1.27 (s, 3H), 1.17 (d, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3)
δC 182.9, 152.2, 146.2, 135.2, 134.7, 127.4, 124.7, 124.4, 121.0, 114.9,
111.1, 75.5, 55.8, 39.8 (2C), 39.5, 39.3, 33.2, 31.5, 26.7, 25.4, 24.1,
22.8, 22.3, 17.0, 16.4, 16.0, 15.9. IR (ATR) νmax 2922, 2852, 1705,
1481, 1465, 1377, 1280, 1220, 1150, 1061, 950 cm−1. HRMS (ESI)
m/z calcd for C28H41O4 [M − H]− 441.3005, found 441.3008.
(6E,10E)-13-((R)-6-Hydroxy-2,5,8-trimethylchroman-2-yl)-2,6,10-
trimethyltrideca-6,10-dienoic Acid (19a). To a solution of 19b (1
equiv) in ethanol (0.08 M) were added N,N,N′,N′-tetramethyldiami-
nomethane (3 equiv) and paraformaldehyde (3 equiv). The reaction
mixture was stirred at 120 °C under microwave irradiation for 1 h.
Then, the reaction was quenched with water. The resulting mixture
was extracted three times with dichloromethane. The combined
organic layers were washed with water and brine, dried over
anhydrous sodium sulfate, filtered, and concentrated under reduced
pressure. The brown oily crude product was used without further
purification. To a solution of 5-dimethylaminomethylchromanol
derivative (1 equiv) in ethanol (0.07 M) was added sodium
cyanoborohydride (5 equiv). The reaction mixture was stirred at
120 °C under microwave irradiation for 45 min. Then, the reaction
was quenched with an aqueous solution of hydrochloric acid (1 M).
The resulting mixture was extracted three times with diethyl ether.
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The combined organic layers were washed with water and brine, dried
over anhydrous sodium sulfate, filtered, and concentrated under
reduced pressure. The residue was purified by column chromatog-
raphy on silica gel eluted with a petroleum ether/acetone (9:1)
mixture to afford 19a with 62% yield. 1H NMR (400 MHz, CDCl3)
δH 6.48 (s, 1H), 5.10 (m, 2H), 2.60 (q, J = 6.8 Hz, 2H), 2.46 (m,
1H), 2.11 (s, 3H), 2.08 (s, 3H), 2.08−2.01 (m, 3H), 2.01−1.89 (m,
4H), 1.91−1.69 (m, 2H), 1.69−1.60 (m, 2H), 1.59 (s, 3H), 1.56 (s,
3H), 1.50−1.45 (m, 1H), 1.43−1.38 (m, 3H), 1.25 (s, 3H), 1.18 (s,
3H), 1.16 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 182.5, 146.0,
145.8, 135.1, 134.7, 124.7, 124.5, 124.2, 120.5, 119.3, 115.4, 74.4,
39.8, 39.5, 39.4, 39.3, 33.2, 31.6, 26.7, 25.4, 23.9 (2C), 22.3, 20.9,
17.0, 16.0, 15.9, 11.1. HRMS (ESI) m/z calcd for C28H41O4 [M −
H]− 441.3005, found 441.3004.
(4E,8E)-11-((R)-2,8-Dimethyl-6-(tosyloxy)chroman-2-yl)-4,8-di-
methylundeca-4,8-dienoic Acid (55). To a solution of 5439 (198 mg,
0.38 mmol, 1 equiv) in 1,4-dioxane (7.5 mL) at 0 °C were added
sulfamic acid (59 mg, 0.60 mmol, 1.6 equiv), 2-methyl-2-butene (2.4
mL, 18.9 mmol, 50 equiv), and a solution of sodium chlorite (60 mg,
0.53 mmol, 1.4 equiv) in water (2.6 mL). The reaction mixture was
stirred at 0 °C for 2 h. Then, the reaction was quenched with sodium
sulfite and diluted with water. The resulting mixture was extracted
three times with diethyl ether. The combined organic layers were
washed with water and brine, dried over anhydrous sodium sulfate,
filtered, and concentrated under reduced pressure. The crude product
55 can be used in the next step without further purification. Rf = 0.31
(petroleum ether/acetone 8:2). 1H NMR (400 MHz, CDCl3) δH 7.72
(d, J = 8.0 Hz, 2H), 7.31 (d, J = 7.9 Hz, 2H), 6.55 (s, 1H), 6.52 (s,
1H), 5.14−5.09 (m, 2H), 2.67−2.63 (m, 2H), 2.45 (s, 3H), 2.45−
2.42 (m, 2H), 2.31−2.27 (m, 2H), 2.05 (s, 3H), 2.10−2.03 (m, 4H),
1.98−1.94 (m, 2H), 1.81−1.69 (m, 2H), 1.68−1.50 (m, 2H), 1.60 (s,
3H), 1.57 (s, 3H), 1.25 (s, 3H). 13C NMR (100 MHz, CDCl3) δC
179.3, 150.8, 145.1, 131.5, 135.2, 133.1, 132.9, 129.7 (2C), 128.7
(2C), 127.6, 125.3, 124.3, 122.0, 121.2, 120.3, 76.3, 39.9, 39.6, 34.4,
33.0, 31.0, 26.6, 24.2, 22.4, 22.2, 21.9, 16.2, 16.1, 16.0. IR (ATR) νmax
2923, 1707, 1598, 1473, 1449, 1372, 1225, 1094, 1049, 814, 696, 552




thylundeca-4,8-dienoic Acid (15b). To a solution of 55 (175 mg,
0.32 mmol, 1 equiv) in methanol (6 mL) was added sodium
hydroxide (467 mg). The mixture was stirred at 70 °C for 1.5 h.
Then, the reaction was quenched with an aqueous solution of
hydrochloric acid (1 M). The resulting mixture was extracted three
times with ethyl acetate. The combined organic layers were washed
with water and brine, dried over anhydrous sodium sulfate, filtered,
and concentrated under reduced pressure. The residue was purified by
column chromatography on silica gel eluted with a petroleum ether/
acetone (8:2) mixture to afford the desired product 15b with 77%
yield over two steps from 54. Yellow oil; Rf = 0.25 (petroleum ether/
acetone 8:2). 1H NMR (400 MHz, CDCl3) δH 6.48 (d, J = 2.6 Hz,
1H), 6.38 (d, J = 2.6 Hz, 1H), 5.16−5.10 (m, 2H), 2.69 (t, J = 7.0 Hz,
2H), 2.44 (t, J = 7.8 Hz, 2H), 2.29 (t, J = 7.8 Hz, 2H), 2.13 (s, 3H),
2.13−2.04 (m, 4H), 1.98−1.95 (m, 2H), 1.83−1.71 (m, 2H), 1.70−
1.50 (m, 2H), 1.60 (s, 3H), 1.58 (s, 3H), 1.26 (s, 3H). 13C NMR
(100 MHz, CDCl3) δC 179.6, 147.9, 146.0, 134.9, 133.1, 127.5, 125.4,
124.6, 121.4, 115.8, 112.8, 75.4, 39.6 (2C), 34.4, 33.1, 31.5, 26.6, 24.2,
22.6, 22.3, 16.2, 16.1, 16.0. IR (ATR) νmax 2921, 1707, 1469, 1218,
1146, 1095, 933, 853 cm−1. HRMS (EI) m/z calcd for C24H34O4
[M+•] 386.2457, found 386.2455.
(4E,8E)-11-((R)-6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)-4,8-
dimethylundeca-4,8-dienoic Acid (15a). To a solution of 15b (1
equiv) in 1,4-dioxane (0.08 M) were added N,N,N′,N′-tetramethyl-
diaminomethane (20 equiv) and paraformaldehyde (20 equiv). The
reaction mixture was stirred at 140 °C under microwave irradiation.
Completion of the reaction was monitored by TLC. Then, the
reaction was quenched with water. The resulting mixture was
extracted three times with dichloromethane. The combined organic
layers were washed with water and brine, dried over anhydrous
sodium sulfate, filtered, and concentrated under reduced pressure.
The brown oily crude product was used without further purification.
To a solution of α-5,7-bis(dimethylaminomethyl)-tocodienol deriva-
tive (1 equiv) in ethanol (0.06 M) was added sodium cyanoborohy-
dride (20 equiv). The reaction mixture was stirred at 150 °C under
microwave irradiation for 0.75−1.5 h. Then, the reaction was
quenched with an aqueous solution of hydrochloric acid (1 M).
The resulting mixture was extracted three times with diethyl ether.
The combined organic layers were washed with water and brine, dried
over anhydrous sodium sulfate, filtered, and concentrated under
reduced pressure. The residue was purified by column chromatog-
raphy on silica gel eluted with a petroleum ether/acetone mixture to
afford 15a with 75% yield. Yellow oil; Rf = 0.22 (petroleum ether/
acetone 8:2). 1H NMR (400 MHz, CDCl3) δH 5.16−5.11 (m, 2H),
2.62 (t, J = 6.8 Hz, 2H), 2.46−2.42 (m, 2H), 2.31−2.27 (m, 2H),
2.16 (s, 3H), 2.12 (s, 3H), 2.11 (s, 3H), 2.09−2.04 (m, 4H), 1.98−
1.94 (m, 2H), 1.87−1.74 (m, 2H), 1.68−1.50 (m, 2H), 1.60 (s, 3H),
1.59 (s, 3H), 1.25 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 179.5,
145.6, 144.7, 134.9, 133.1, 125.4, 124.7, 122.8, 121.2, 118.7, 117.5,
74.4, 39.6 (2C), 34.4, 33.0, 31.7, 26.6, 23.8, 22.3, 20.9, 16.1, 16.0,
12.4, 11.9, 11.4. IR (ATR) νmax 3459, 2922, 2852, 1708, 1453, 1378,




ylate (25). To a solution of diacid 5647 (1 equiv) in
dimethylformamide (0.13 M) were added sodium bicarbonate (4
equiv) and iodomethane (4 equiv). The reaction mixture was stirred
at 120 °C under microwave irradiation for 2 h. Then, the reaction was
quenched with water. The resulting mixture was extracted three times
with diethyl ether. The combined organic layers were washed with
water and brine, dried over anhydrous sodium sulfate, filtered, and
concentrated under reduced pressure. The residue was purified by
column chromatography on silica gel eluted with a petroleum ether/
acetone mixture 95:5 to afford 25 with 85% yield. Colorless oil; Rf =
0.3 (petroleum ether/ethyl acetate 9:1). 1H NMR (400 MHz, CDCl3)
δH 10.83 (s, 1H), 6.73 (dd, J = 7.3, 5.9 Hz, 1H), 6.68 (s, 1H), 5.17−
5.08 (m, 2H), 3.93 (s, 3H), 3.72 (s, 3H), 2.98 (t, J = 6.9 Hz, 2H),
2.26 (s, 2H), 2.19−2.15 (m, 3H), 2.14−2.03 (m, 6H), 1.97 (d, J = 7.9
Hz, 2H), 1.82 (d, J = 1.2 Hz, 3H), 1.74 (d, J = 6.8 Hz, 2H), 1.64−
1.53 (m, 8H), 1.25 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 172.2,
168.8, 156.3, 145.3, 142.5, 136.3, 135.2, 134.0, 127.5, 125.2, 124.4,
120.8, 117.6, 109.0, 74.5, 52.0, 51.8, 39.7, 39.5, 38.3, 31.6, 27.5, 26.7,
23.7, 23.0, 22.2, 17.2, 16.1, 16.0, 12.5. HRMS (ESI) m/z calcd for
C30H42O6Na [M + Na]
+ 521.2879, found 521.2878.
(2R)-2,8,-Dimethyl-2-[(3E,7E)-4,8,12-trimethyldeca-3,7,11-trien-
1-yl]-3,4-dihydro-2H-1-benzopyran-6-yl-4-methylbenzene-1-sulfo-
nate (57). To a solution of 6d (600 mg; 1.51 mmol; 1 equiv) in
dichloromethane (33 mL) were added 4-toluenesulfonyl chloride
(316.5 mg; 1.66 mmol; 1.1 equiv) and trimethylamine (252.2 μL;
1.81 mmol; 1.2 equiv). The reaction mixture was stirred at room
temperature for 4 h. Then, the reaction was quenched with a saturated
aqueous solution of sodium bicarbonate after being extracted 3 times
with diethyl ether. The combined organic layers were washed twice
with water and once with brine and afterward dried over anhydrous
sodium sulfate, filtrated through cotton, and evaporated under
reduced pressure. The residue was purified by automated flash
chromatography on silica gel eluted with a mixture of petroleum
ether/acetone (9:1). The desired product was obtained in 60% yield.
Light-brown oil, Rf = 0.43 (petroleum ether/acetone 8:2)
1H NMR
(400 MHz, CDCl3) δH 7.72 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 7.9 Hz,
2H), 6.56 (d, J = 2.6 Hz, 1H), 6.52 (d, J = 2.4 Hz, 1H), 5.14−5.07
(m, 3H), 2.67−2.63 (m, 2H), 2.45 (s, 3H), 2.13−2.02 (m, 6H), 2.05
(s, 3H), 1.99−1.94 (m, 4H), 1.82−1.70 (m, 2H), 1.67 (s, 3H), 1.64−
1.52 (m, 2H), 1.59 (s, 3H), 1.58 (s, 6H), 1.25 (s, 3H). 13C NMR
(100 MHz, CDCl3) δC 150.8, 145.1, 141.5, 135.5, 135.2, 132.9, 131.4,
129.7 (2C), 128.7 (2C), 127.6, 124.5, 124.2, 124.1, 122.0, 121.2,
120.3, 76.3, 39.9, 39.8 (2C), 31.0, 26.9, 26.7, 25.9, 24.2, 22.4, 22.2,
21.8, 17.8, 16.2, 16.1, 16.0. IR (ATR) νmax 2919, 2853, 1473, 1449,
1373, 1189, 1093, 984, 813, 581 cm−1. HRMS (FAB) m/z calcd for
C34H46O4S [M
+] 550.3117, found 550.3116.
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Cross-Metathesis Procedure for the Preparation of 58−60.
To a solution of tosylated δ-tocotrienol 57 (30 mg, 0.06 mmol, 1
equiv) in degassed deuterated chloroform (0.7 mL) were added
methyl acrylate (10.8 μL, 0.12 mmol, 2.4 equiv) and Grubbs-II
catalyst (0.1 equiv). The reaction mixture was refluxed for 3 days.
Then, the solvent was removed under reduced pressure. The residue
was purified by preparative TLC on silica gel eluted with a
cyclohexane/ethyl acetate mixture (7:2).
(2E,6E,10E)-Methyl-13-((R)-2,8-dimethyl-6-(tosyloxy)chroman-2-
yl)-6,10-dimethyltrideca-2,6,10-trienoate (58). 58 was obtained
from 57 and methyl acrylate with 10% yield. Yellow oil; Rf = 0.58
(cyclohexane/ethyl acetate 7:2). 1H NMR (400 MHz, CDCl3) δH
7.72 (d, J = 7.8 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 6.98−6.91 (m,
1H), 6.56 (s, 1H), 6.52 (s, 1H), 5.81 (d, J = 15.5 Hz, 1H), 5.14−5.10
(m, 2H), 3.72 (s, 3H), 2.69−2.61 (m, 2H), 2.45 (s, 3H), 2.31−2.26
(m, 2H), 2.12−2.08 (m, 6H), 2.05 (s, 3H), 1.98−1.94 (m, 2H),
1.82−1.70 (m, 2H), 1.67−1.50 (m, 2H), 1.58 (s, 6H), 1.25 (s, 3H).
13C NMR (100 MHz, CDCl3) δC 167.3, 150.8, 149.5, 145.1, 141.5,
136.3, 133.6, 133.0, 129.7 (2C), 128.7 (2C), 127.6, 125.3, 124.2,
122.0, 121.2, 121.0, 120.3, 76.3, 51.6, 39.9, 39.7, 38.0, 31.0, 30.9, 26.6,
24.2, 22.4, 22.2, 21.9, 16.2, 16.1, 16.0. IR (ATR) νmax 2925, 2852,
1722, 1473, 1450, 1371, 1189, 1174, 1093, 984 cm−1. MS (EI) m/z
calcd for C34H44O6S [M
+•] 580.3, found 580.3.
(2E,6E)-Methyl-9-((R)-2,8-dimethyl-6-(tosyloxy)chroman-2-yl)-6-
methylnona-2,6-dienoate (59). 59 was obtained from 57 and methyl
acrylate with 30% yield. Yellow oil; Rf = 0.53 (cyclohexane/ethyl
acetate 7:2). 1H NMR (400 MHz, CDCl3) δH 7.73 (d, J = 8.0 Hz,
2H), 7.31 (d, J = 7.9 Hz, 2H), 6.98−6.90 (m, 1H), 6.56 (s, 1H), 6.53
(s, 1H), 5.81 (d, J = 15.7 Hz, 1H), 5.17−5.13 (m, 1H), 3.71 (s, 3H),
2.68−2.61 (m, 2H), 2.45 (s, 3H), 2.32−2.26 (m, 2H), 2.12−2.09 (m,
2H), 2.05 (s, 3H), 1.81−1.67 (m, 4H), 1.62−1.49 (m, 2H), 1.58 (s,
3H), 1.25 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 167.3, 150.8,
149.4, 145.1, 141.6, 133.9, 133.0, 129.7 (2C), 128.7 (2C), 127.6,
125.3, 122.0, 121.2, 121.1, 120.3, 76.2, 51.6, 39.9, 38.0, 31.0, 30.8,
24.1, 22.4, 22.2, 21.8, 16.2, 15.9. IR (ATR) νmax 2925, 2852, 1722,
1473, 1450, 1371, 1189, 1176, 1093, 984 cm−1. MS (EI) m/z calcd for
C29H36O6S [M
+•] 512.2, found 512.3.
(R,E)-Methyl-5-(2,8-dimethyl-6-(tosyloxy)chroman-2-yl)pent-2-
enoate (60). 60 was obtained from 57 and methyl acrylate with 49%
yield. Yellow oil; Rf = 0.44 (cyclohexane/ethyl acetate 7:2).
1H NMR
(400 MHz, CDCl3) δH 7.73 (d, J = 8.1 Hz, 2H), 7.31 (d, J = 8.0 Hz,
2H), 7.03−6.96 (m, 1H), 6.57 (s, 1H), 6.53 (s, 1H), 5.83 (d, J = 15.6
Hz, 1H), 3.72 (s, 3H), 2.73−2.61 (m, 2H), 2.45 (s, 3H), 2.39−2.33
(m, 2H), 2.04 (s, 3H), 1.82−1.68 (m, 4H), 1.25 (s, 3H). 13C NMR
(100 MHz, CDCl3) δC 167.2, 150.4, 149.4, 145.1, 141.7, 132.9, 129.7
(2C), 128.7 (2C), 127.6, 122.2, 121.1, 121.0, 120.4, 75.8, 51.6, 38.3,
31.1, 26.6, 23.9, 22.3, 21.9, 16.2. IR (ATR) νmax 2926, 2851, 1722,
1473, 1371, 1189, 1177, 1094, 984 cm−1. MS (EI) m/z calcd for
C24H28O6S [M
+•] 444.2, found 444.2.
(R,E)-Methyl-5-(2,8-dimethyl-6-(tosyloxy)chroman-2-yl)-2-meth-
ylpent-2-enoate (61). To a solution of 57 (30 mg, 0.05 mmol, 1
equiv) in degassed deuterated chloroform (0.7 mL) were added
methyl methacrylate (6.4 μL, 0.06 mmol, 1.2 equiv) and Hoveyda−
Grubbs-II catalyst (3.55 mg, 0.005 mmol, 0.1 equiv). The reaction
mixture was stirred under microwave irradiation at 120 °C for 2.5 h.
Then, the solvent was removed under reduced pressure. The residue
was purified by preparative TLC on silica gel eluted with a
cyclohexane/ethyl acetate mixture 7:2 to afford 61 as an oil with
21% yield. Yellow oil; Rf = 0.41 (cyclohexane/ethyl acetate 7:2).
1H
NMR (400 MHz, CDCl3) δH 7.73 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 7.8
Hz, 2H), 6.77 (t, J = 7.3 Hz, 1H), 6.57 (s, 1H), 6.53 (s, 1H), 3.72 (s,
3H), 2.73−2.62 (m, 2H), 2.45 (s, 3H), 2.34−2.28 (m, 2H), 2.05 (s,
3H), 1.82 (s, 3H), 1.79−1.69 (m, 2H), 1.67−1.56 (m, 2H), 1.26 (s,
3H). 13C NMR (100 MHz, CDCl3) δC 168.7, 150.5, 145.1, 142.2,
141.7, 132.9, 129.7 (2C), 128.7 (2C), 127.8, 127.6, 122.1, 121.0,
120.4, 75.9, 51.9, 38.6, 31.1, 24.0, 23.0, 22.3, 21.9, 16.2, 12.4. IR
(ATR) νmax 2924, 2852, 1711, 1471, 1369, 1189, 1176, 1091, 982,
813 cm−1. MS (EI) m/z calcd for C25H30O6S [M
+•] 458.2, found
458.1.
Cross-Metathesis Procedure for the Preparation of 62 and
63. To a solution of 57 (30 mg, 0.05 mmol, 1 equiv) in degassed
deuterated chloroform (0.7 mL) were added 2-methylene-1,3-
propanediacetate (10 mg, 0.05 mmol, 1.2 equiv) and Grubbs-II
catalyst (4.2 mg, 0.005 mmol, 0.1 equiv). The reaction mixture was
stirred under microwave irradiation at 120 °C for 2 h. Then, the
solvent was removed under reduced pressure. The residue was
purified by preparative TLC on silica gel eluted with a cyclohexane/
ethyl acetate mixture 7:2 to afford the desired products as oil.
(R,E)-2-(7-(2,8-Dimethyl-6-(tosyloxy)chroman-2-yl)-4-methyl-
hept-4-en-1-ylidene)propane-1,3-diyl Diacetate (62). 62 was
obtained from 57 and 2-methylene-1,3-propanediacetate with 27%
yield. Yellow oil; Rf = 0.37 (cyclohexane/ethyl acetate 7:2).
1H NMR
(400 MHz, CDCl3) δH 7.72 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.0 Hz,
2H), 6.56 (d, J = 2.8 Hz, 1H), 6.52 (d, J = 2.8 Hz, 1H), 5.74 (t, J = 7.3
Hz, 1H), 5.13 (td, J = 1.1, 7.1 Hz, 1H), 4.64 (s, 2H), 4.55 (s, 2H),
2.68−2.64 (m, 2H), 2.45 (s, 3H), 2.24 (dd, J = 7.4 Hz, 15.0 Hz, 2H),
2.13−2.01 (m, 4H), 2.05 (s, 9H), 1.80−1.71 (m, 2H), 1.67−1.50 (m,
2H), 1.58 (s, 3H), 1.25 (s, 3H). 13C NMR (100 MHz, CDCl3) δC
171.1, 170.9, 150.7, 145.1, 141.5, 136.5, 135.4, 134.3, 132.9, 129.7
(2C), 129.1, 128.7 (2C), 127.5, 125.1, 122.0, 121.2, 120.3, 76.2, 66.8,
59.9, 39.9, 39.1, 31.0, 29.8, 26.3, 24.1, 22.4, 22.2, 21.8, 21.1, 16.2,
15.9. IR (ATR) νmax 2925, 2853, 1711, 1361, 1221, 1178, 735 cm
−1.




propane-1,3-diyl Diacetate (63). 63 was obtained from 57 and 2-
methylene-1,3-propanediacetate with 38% yield. Yellow oil; Rf = 0.22
(cyclohexane/ethyl acetate 7:2). 1H NMR (400 MHz, CDCl3) δH
7.72 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 6.56 (d, J = 2.8 Hz,
1H), 6.52 (d, J = 2.8 Hz, 1H), 5.77 (t, J = 7.4 Hz, 1H), 4.68−4.60 (m,
2H), 4.55 (s, 2H), 2.69−2.64 (m, 2H), 2.45 (s, 3H), 2.33−2.27 (m,
2H), 2.05 (s, 3H), 2.03 (s, 6H), 1.81−1.57 (m, 4H), 1.25 (s, 3H). 13C
NMR (100 MHz, CDCl3) δC 171.1, 170.9, 150.5, 145.1, 141.7, 136.3,
132.9, 129.7 (2C), 129.4, 128.7 (2C), 127.6, 122.1, 121.0, 120.4, 75.9,
66.7, 59.8, 39.5, 31.0, 24.0, 22.3, 22.1, 21.8, 21.1, 21.0, 16.2. IR (ATR)
νmax 2917, 2849, 1734, 1471, 1370, 1224, 1178, 734 cm
−1. HRMS
(FAB) m/z calcd for C28H34O8S [M
+•] 530.1974, found 530.1977.
(R,E)-2-(7-(6-Hydroxy-2,8-dimethylchroman-2-yl)-4-methylhept-
4-en-1-ylidene)propane-1,3-diol (28). To a solution of 62 (1 equiv)
in methanol (0.03 M), potassium hydroxide (400 mg) was added.
The mixture was stirred at 70 °C until completion of the reaction,
monitored by TLC. Then, the reaction was quenched with an
aqueous solution of hydrochloric acid (1 M). The resulting mixture
was extracted three times with dichloromethane. The combined
organic layers were washed with water and brine, dried over
anhydrous sodium sulfate, filtered, and concentrated under reduced
pressure. The residue was purified by column chromatography on
silica gel eluted with a petroleum ether/acetone (9:1 to 8:2) mixture
to afford 28 with 53% yield. Pale-yellow oil; Rf = 0.26 (petroleum
ether/acetone 7:3). 1H NMR (400 MHz, CDCl3) δH 6.48 (d, J = 2.4
Hz, 1H), 6.39 (d, J = 2.6 Hz, 1H), 5.52 (t, J = 7.3 Hz, 1H), 5.13 (td, J
= 1.1, 7.1 Hz, 1H), 4.29 (s, 2H), 4.20 (s, 2H), 2.69 (t, J = 6.7 Hz,
2H), 2.52 (bs, 3H), 2.20−2.16 (m,2H), 2.14−2.08 (m, 2H), 2.12 (s,
3H), 2.03−2.00 (m, 2H), 1.83−1.70 (m, 2H), 1.66−1.48 (m, 2H),
1.58 (s, 3H), 1.26 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 147.9,
146.0, 137.1, 134.3, 131.0, 127.5, 125.3, 121.4, 115.8, 112.7, 75.4,
67.9, 60.3, 39.5, 39.4, 31.5, 26.0, 24.2, 22.6, 22.2, 16.2, 16.0. IR (ATR)
νmax 3335, 2926, 1608, 1472, 1220, 1147, 994, 854 cm
−1. HRMS (EI)
m/z calcd for C22H32O4 [M
+•] 360.2301, found 360.2299.
(R)-2-(3-(6-Hydroxy-2,8-dimethylchroman-2-yl)propylidene)-
propane-1,3-diol (29). 29 was obtained from 63 with 57% yield using
the method described above for the preparation of 28. Pale-yellow oil;
Rf = 0.21 (petroleum ether/acetone 7:3).
1H NMR (400 MHz,
CDCl3) δH 6.48 (d, J = 2.4 Hz, 1H), 6.38 (d, J = 2.8 Hz, 1H), 5.58 (t,
J = 7.5 Hz, 1H), 4.31 (m, 2H), 4.20 (s, 2H), 2.70 (dd, J = 6.6 Hz, 12.9
Hz, 2H), 2.24 (dd, J = 7.8, 16.5 Hz, 2H), 2.12 (s, 3H), 1.82−1.54 (m,
4H), 1.25 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 148.0, 141.4,
137.1, 131.3, 127.5, 121.3, 115.8, 112.8, 75.1, 67.8, 60.2, 39.6, 31.6,
24.1, 22.5, 21.8, 16.2. IR (ATR) νmax 3334, 2921, 1608, 1466, 1219,
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1st step: A 0.02 M solution of 58 (26.3 mg, 1 equiv) in 4 mL of a
mixture of THF/MeOH/H2O (3:1:1) was treated with LiOH (5.4
mg, 4.3 equiv). The reaction mixture was stirred at 40 °C overnight.
Completion of the reaction was monitored by TLC using a mixture of
petroleum ether/acetone/dichloromethane (7:2:1) as the mobile
phase. The reaction was quenched with 10% hydrochloric acid and
extracted three times with ethyl acetate. The combined organic layers
were washed twice with water and once with brine, dried over
anhydrous sodium sulfate, and filtered. Removal of the solvent under
reduced pressure yielded the corresponding carboxylic acid that was
used without further purification. 2nd step: Removal of the tosyl
group was achieved in a mixture of methanol (0.01 M) and 2 M
aqueous potassium hydroxide solution (1:1). The reaction mixture
was refluxed for 6 h. Completion of the reaction was monitored by
TLC using a mixture of petroleum ether/acetone/dichloromethane
(7:2:1) as the mobile phase. The reaction was quenched with 10%
hydrochloric acid and extracted three times with ethyl acetate. The
combined organic layers were washed twice with water and once with
brine, dried over anhydrous sodium sulfate, and filtered. Removal of
the solvent under reduced pressure yielded the crude phenol
derivative. Purification was achieved by silica gel preparative TLC,
leading to 14 with 16% yield from 58. Light-yellow oil; Rf = 0.53
(petroleum ether/acetone/dichloromethane 7:2:1). 1H NMR (400
MHz, CDCl3) δH 7.09−7.02 (m, 1H), 6.48 (s, 1H), 6.38 (s, 1H),
5.86−5.77 (m, 1H), 5.16−5.09 (m, 2H), 2.72−2.66 (m, 2H), 2.35−
2.23 (m, 2H), 2.16−2.01 (m, 10H), 1.98−1.93 (m, 2H), 1.82−1.71
(m, 2H), 1.64−1.52 (m, 8H), 1.26 (s, 3H). 13C NMR (100 MHz,
CDCl3) δC 171.6, 152.3, 147.8, 146.1, 134.9, 133.4, 127.5, 125.5,
124.6, 121.3, 120.6, 115.8, 112.7, 75.4, 39.6, 39.5, 37.8, 31.5, 31.0,
26.5, 24.3, 22.6, 22.3, 16.2, 16.1, 16.0. HRMS (ESI) m/z calcd for
C26H35O4 [M − H]− 411.2535, found 411.2531.
(2E,6E)-9-[(2R)-6-Hydroxy-2,8-dimethyl-3,4-dihydro-2H-1-benzo-
pyran-2-yl]-6-methylnona-2,6-dienoic Acid (16). 16 was obtained
from 59 with 31% yield using the two-step procedure described above
for 58. Light-yellow oil; Rf = 0.47 (petroleum ether/acetone/
dichloromethane 7:2:1). 1H NMR (400 MHz, CDCl3) δH 7.08−
6.96 (m, 1H), 6.48 (s, 1H), 6.38 (s, 1H), 5.84−5.78 (m, 1H), 5.19−
5.13 (m, 1H), 2.71−2.65 (m, 2H), 2.35−2.29 (m, 2H), 2.17−2.07
(m, 7H), 1.79−1.72 (m, 2H), 1.69−1.47 (m, 6H), 1.26 (s, 3H). 13C
NMR (100 MHz, CDCl3) δC 171.4, 152.1, 147.8, 146.1, 133.5, 127.5,
125.7, 121.4, 120.6, 115.8, 112.7, 75.4, 39.6, 37.8, 31.5, 30.9, 24.2,
22.6, 22.3, 16.2, 15.9. HRMS (ESI) m/z calcd for C21H27O4 [M −
H]− 343.1909, found 343.1906.
(2E)-5-[(2R)-6-Hydroxy-2,8-dimethyl-3,4-dihydro-2H-1-benzo-
pyran-2-yl]pent-2-enoic Acid (17). 17 was obtained with 17% yield
from 60 using the two-step procedure described above for 58. Light-
yellow oil; 17% total yield; Rf = 0.36 (petroleum ether/acetone/
dichloromethane 7:2:1). 1H NMR (400 MHz, CDCl3) δH 7.17−7.08
(m, 1H), 6.48 (s, 1H), 6.39 (s, 1H), 5.84 (d, J = 15.6 Hz, 1H), 2.77−
2.64 (m, 2H), 2.44−2.38 (m, 2H), 2.11 (s, 3H), 1.87−1.60 (m, 4H),
1.26 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 171.5, 152.5, 148.0,
145.7, 127.6, 121.1, 120.5, 115.9, 112.7, 74.9, 37.9, 31.6, 26.8, 23.9,
22.5, 16.2. HRMS (ESI) m/z calcd for C16H19O4 [M − H]−
275.1283, found 275.1281.
(R,E)-5-(6-Hydroxy-2,8-dimethylchroman-2-yl)-2-methylpent-2-
enoic Acid (18). To a solution of 61 (48 mg, 0.1 mmol, 1 equiv) in a
mixture of water/THF (2:1; 3 mL) was added potassium hydroxide
(337 mg). The mixture was stirred at 70 °C for 18 h. Then, the
reaction was quenched with an aqueous solution of hydrochloric acid
(1 M). The resulting mixture was extracted three times with diethyl
ether. The combined organic layers were washed with water and
brine, dried over anhydrous sodium sulfate, filtered, and concentrated
under reduced pressure. The residue was purified by preparative TLC
eluted with a petroleum ether/acetone (75:25) mixture to afford the
desired product 18 with 20% yield. Yellow oil; Rf = 0.4 (petroleum
ether/acetone 7:3). 1H NMR (400 MHz, CDCl3) δH 6.92 (td, J = 1.4
Hz, 7.5 Hz, 1H), 6.48 (d, J = 2.5 Hz, 1H), 6.38 (d, J = 3.0 Hz, 1H),
2.74−2.69 (m, 2H), 2.36 (dd, J = 7.8 Hz, 15.6 Hz, 2H), 2.12 (s, 3H),
1.83 (s, 3H), 1.81−1.73 (m, 3H), 1.68−1.61 (m, 1H), 1.27 (s, 3H).
13C NMR (100 MHz, CDCl3) δC 172.9, 148.0, 145.8, 145.2, 127.5,
121.2, 115.9, 112.7, 75.0, 38.4, 31.6, 29.4, 23.9, 23.4, 22.5, 16.2, 12.0.
IR (ATR) νmax 3365, 2925, 1682, 1639, 1607, 1470, 1426, 1378, 1291,
1216, 1145, 1096, 853 cm−1. HRMS (ESI) m/z calcd for C17H21O4
[M − H]− 289.1440, found 289.1435.
2-((4E,8E)-11-((R)-6-Acetoxy-2,8-dimethylchroman-2-yl)-4,8-di-
methylundeca-4,8-dien-1-ylidene)propane-1,3-diyl Diacetate (65).
To a solution of δ-AC (27d) (289 mg, 0.67 mmol, 1 equiv) in
pyridine (15 mL) was added acetic anhydride (431 μL, 3.37 mmol, 5
equiv). The reaction mixture was stirred at room temperature for 24
h. Then, the reaction was quenched with a saturated aqueous solution
of sodium bicarbonate. The resulting mixture was extracted three
times with ethyl acetate. The combined organic layers were washed
with water and brine, dried over anhydrous sodium sulfate, filtered,
and concentrated under reduced pressure. The residue was purified by
column chromatography on silica gel eluted with a petroleum ether/
acetone (9:1) mixture to afford the desired product 65 with 85%
yield. Pale-yellow oil; Rf = 0.48 (petroleum ether/acetone 85:15).
1H
NMR (400 MHz, CDCl3) δH 6.66 (s, 1H), 6.61 (s, 1H), 5.75 (t, J =
7.4 Hz, 1H), 5.14−5.09 (m, 2H), 4.64 (s, 2H), 4.55 (s, 2H), 2.75−
2.71 (m, 2H), 2.26−2.21 (m, 2H), 2.25 (s, 3H), 2.14−2.01 (m, 7H),
2.12 (s, 3H), 2.05 (s, 6H), 1.98−1.94 (m, 2H), 1.83−1.70 (m, 4H),
1.66−1.53 (m, 2H), 1.58 (s, 3H), 1.27 (s, 3H). 13C NMR (100 MHz,
CDCl3) δC 171.6, 170.9, 170.5, 149.8, 142.6, 136.5, 135.3, 133.9,
129.1, 127.5, 125.3, 124.3, 121.3, 121.0, 119.2, 76.0, 66.8, 59.9, 40.0,
39.7, 39.1, 31.0, 26.7, 26.3, 24.2, 22.5, 22.2, 21.2, 21.1 (2C), 16.3, 16.0
(2C). IR (ATR) νmax 2924, 2853, 1739, 1475, 1368, 1204, 1020, 801
cm−1. MS (EI) m/z calcd for C33H46O7 [M
+•] 554.3, found 554.5.
2-(11-( (R)-6-Acetoxy-2,8-dimethylchroman-2-yl ) -4 ,8-
dimethylundecyl)propane-1,3-diyl Diacetate (66). To a solution of
65 (140 mg, 0.25 mmol, 1 equiv) in ethyl acetate (10 mL) was added
under a nitrogen atmosphere palladium over charcoal (loading 10 wt
%), and then, hydrogen was bubbled in the organic phase. The
reaction mixture was stirred at room temperature for 40 min under a
hydrogen atmosphere. Completion of the reaction was monitored by
1H NMR. The resulting mixture was filtered on Celite, washed with
ethyl acetate, and concentrated under reduced pressure. The residue
was purified by column chromatography on silica gel eluted with a
petroleum ether/acetone (95:5) mixture to afford the desired product
66 as a diastereomeric mixture with 52% yield. Pale-yellow oil; Rf =
0.50 (petroleum ether/acetone 8:2). 1H NMR (400 MHz, CDCl3) δH
6.66 (s, 1H), 6.60 (s, 1H), 4.04 (qd, J = 5.8, 11.1 Hz, 4H), 2.74−2.67
(m, 2H), 2.25 (s, 3H), 2.13 (s, 3H), 2.05 (s, 6H), 2.01−1.97 (m, 1H),
1.83−1.68 (m, 2H), 1.60−1.50 (m, 2H), 1.44−1.28 (m, 10H), 1.25
(s, 6H), 1.16−0.99 (m, 5H), 0.85−0.83 (m, 6H). 13C NMR (100
MHz, CDCl3) δC 171.3 (2C), 170.5, 149.9, 142.5, 127.4, 121.2, 121.0,
119.2, 76.2, 64.5, 64.4, 40.3 (2C), 37.6−37.2 (7C), 32.8 (2C), 31.0
(2C), 28.6, 24.6, 24.4, 22.6, 21.2, 21.1, 21.0 (2C), 19.8−19.7 (4C),
16.3. MS (EI) m/z calcd for C33H52O7 [M
+•] 560.4, found 560.5.
2-(11-( (R)-6-Hydroxy-2,8-dimethylchroman-2-yl ) -4 ,8-
dimethylundecyl)propane-1,3-diol (26). To a solution of 66 (43 mg,
0.08 mmol, 1 equiv) in methanol (3 mL) was added under a nitrogen
atmosphere a solution of MeONa 0.1 M (2.33 mL, 0.23 mmol, 3
equiv). The reaction mixture was stirred at room temperature for 40
min under a nitrogen atmosphere. Then, the reaction was quenched
with an aqueous solution of hydrochloric acid (1 M). The resulting
mixture was extracted three times with dichloromethane. The
combined organic layers were washed with water and brine, dried
over anhydrous sodium sulfate, filtered, and concentrated under
reduced pressure to afford the desired product 26 with 99% yield.
Pale-yellow oil; Rf = 0.15 (petroleum ether/acetone 85:15).
1H NMR
(400 MHz, CDCl3) δH 6.47 (s, 1H), 6.38 (s, 1H), 3.85−3.83 (m,
2H), 3.69−3.65 (m, 2H), 2.94 (bs, 2H, OH), 2.70−2.65 (m, 2H),
2.11 (s, 3H), 1.80−1.70 (m, 3H), 1.56−1.52 (m, 1H), 1.45−1.15 (m,
19H), 1.14−1.00 (m, 4H), 0.84−0.83 (m, 6H). 13C NMR (100 MHz,
CDCl3) δC 148.1, 145.9, 127.3, 121.4, 115.8, 112.7, 75.6 (3C), 66.7
(2C), 41.9, 39.5 (4C), 37.5−37.1 (9C), 32.8−32.5 (6C), 31.5−31.4
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(4C), 29.8, 28.1, 24.8 (2C), 24.6−24.3 (6C), 22.6, 21.1−20.8 (4C),
20.0−19.8 (5C), 16.2. IR (ATR) νmax 3361, 2925, 2855, 1466, 1377,
1220, 1032, 855 cm−1. HRMS (ESI) m/z calcd for C27H45O4 [M −
H]− 433.3318, found 433.3313.
2-((4E,8E)-11-((R)-6-Hydroxy-2,8-dimethyl-5,7-bis((4-methylpi-
perazin-1-yl)methyl)chroman-2-yl)-4,8-dimethylundeca-4,8-dien-
1-ylidene)propane-1,3-diol (40). To a solution of 27d (100 mg, 0.24
mmol, 1 equiv) in methanol (5 mL) under a nitrogen atmosphere was
added the Mannich alkylating reagent (4.8 mmol, 20 equiv), freshly
prepared from paraformaldehyde and N-methylpiperazine (547 mg,
4.8 mmol, 20 equiv). The reaction mixture was refluxed for 48 h.
Then, the solvent was evaporated under reduced pressure. The crude
residue was diluted into methyl-tert-butyl ether (MTBE). The organic
layer was stirred for 30 min with an aqueous saturated solution of
sodium phosphate and washed with water (3 × 20 mL) and brine. It
was then dried over anhydrous sodium sulfate and filtered. Removal of
the solvent under reduced pressure led to the final bis-Mannich base
characterized without further purification (92% yield). Rf (neutral
Al2O3) = 0.35 (DCM/MeOH 9.5/0.5).
1H NMR (500 MHz,
methanol-d4) δH 5.55 (t, J = 7.2 Hz, 1H), 5.14 (t, J = 7.2 Hz, 1H),
5.12 (t, J = 7.2 Hz, 1H), 4.15 (s, 2H), 4.08 (s, 2H), 3.65 (s, 2H), 3.60
(s, 2H), 2.74 (t, J = 5.9 Hz, 2H), 2.67−2.35 (m, 16H), 2.29 (s, 6H),
2.24−2.19 (m, 2H), 2.13 (s, 3H), 2.12−2.09 (m, 2H), 2.07−2.05 (m,
2H), 2.04−1.96 (m, 4H), 1.83−1.72 (m, 2H), 1.59 (s, 3H), 1.52 (s,
3H), 1.62−1.47 (m, 2H), 1.24 (s, 3H). 13C NMR (125 MHz,
methanol-d4) δC 151.7, 145.8, 139.3, 135.9, 135.5, 130.7, 126.5, 125.8,
125.7, 121.3, 121.1, 118.5, 75.5, 65.6, 58.3, 55.8, 55.9 (2C), 55.5, 54.8,
53.0, 53.1 (2C), 45.9 (2C), 40.5, 40.3, 40.2, 32.7, 27.6, 27.1, 24.3,
22.3, 21.2, 16.0, 16.1, 12.0. HRMS (FAB) m/z calcd for C33H44O6 [M
+ H]+ 653.5000, found 653.4992.
2-((4E,8E)-11-((R)-6-Hydroxy-2,8-dimethyl-5-(pyrrolidin-1-
ylmethyl)chroman-2-yl)-4,8-dimethylundeca-4,8-dien-1-ylidene)-
propane-1,3-diol (35). To a solution of 27d (100 mg, 0.24 mmol, 1
equiv) in methanol (5 mL) under a nitrogen atmosphere, we added
pyrrolidine (41 mg, 0.48 mmol, 2 equiv), either N,N,N,N-tetramethyl-
methylene diamine (TMMDA) or the iminium freshly prepared from
paraformaldehyde and the corresponding secondary amine. The
reaction mixture was refluxed for 5 h. Then, the solvent was
evaporated under reduced pressure. The crude residue was diluted
into methyl-tert-butyl ether (MTBE). The organic layer was stirred for
30 min with an aqueous saturated solution of sodium phosphate and
washed with water (3 × 20 mL) and brine. It was then dried over
anhydrous sodium sulfate and filtered. Removal of the solvent under
reduced pressure led to the final Mannich base 35 with 90% yield
characterized without further purification. Rf (neutral Al2O3) = 0.35
(DCM/petroleum ether/MeOH 5:5:0.3). 1H NMR (500 MHz,
acetone-d6) δH 6.39 (s, 1H), 5.47 (t, J = 7.2 Hz, 1H), 5.16 (t, J = 7.2
Hz, 1H), 5.12 (t, J = 7.2 Hz, 1H), 4.17 (s, 2H), 4.10 (s, 2H), 3.66 (t, J
= 3.9 Hz, 4H), 3.78 (s, 2H), 2.67 (t, J = 6.8 Hz, 2H), 2.63 (t, J = 5.0
Hz, 4H), 2.22 (s, 3H), 2.20−2.11 (m, 4H), 2.09−2.06 (m, 2H), 2.07
(s, 3H), 2.01−1.96 (m, 4H), 1.85−1.71 (m, 4H), 1.63−1.49 (m, 8H),
1.23 (s, 3H).13C NMR (125 MHz, acetone-d6) δC 151.7, 145.1, 140.2,
135.5, 135.3, 127.8, 126.2, 125.4, 125.2, 119.2, 118.0, 117.0, 74.7,
65.9, 58.9, 54.2 (2C), 54.1, 46.1, 40.5, 40.3, 39.7, 32.3, 27.2, 26.7,
24.2, 24.1, 22.8, 21.1, 16.3, 16.1, 15.9. HRMS (FAB) m/z calcd for
C32H50NO4 [M + H]
+ 512.3735, found 512.3758.
2-((4E,8E)-11-((R)-5-((Dimethylamino)methyl)-6-hydroxy-2,8-di-
methylchroman-2-yl)-4,8-dimethylundeca-4,8-dien-1-ylidene)-
propane-1,3-diol (36). 36 was obtained from 27d (100 mg, 0.24
mmol, 1 equiv), paraformaldehyde, and TMMDA (68 μL, 0.48 mmol,
2 equiv) with 90% yield using the same method as described above for
35. Rf (neutral Al2O3) = 0.40 (DCM/petroleum ether/MeOH
5:5:0.3). 1H NMR (500 MHz, acetone-d6) δH 6.39 (s, 1H), 5.47 (t, J
= 7.2 Hz, 1H), 5.16 (t, J = 7.2 Hz, 1H), 5.13 (t, J = 7.2 Hz, 1H), 4.17
(s, 2H), 4.10 (s, 2H), 3.57 (s, 2H), 2.67 (t, J = 6.8 Hz, 2H), 2.29 (s,
6H), 2.22 (s, 3H), 2.20−2.11 (m, 4H), 2.09−2.06 (m, 2H), 2.07 (s,
3H), 2.01−1.96 (m, 4H), 1.85−1.71 (m, 2H), 1.63−1.49 (m, 2H),
1.59 (s, 6H), 1.23 (s, 3H). 13C NMR (125 MHz, acetone-d6) δC
151.7, 145.1, 140.2, 135.5, 135.3, 127.8, 126.3, 125.4, 125.2, 119.7,
117.7, 117.0, 74.7, 66.9, 58.9, 58.2, 44.6 (2C), 40.5, 40.3, 39.7, 32.3,
27.2, 26.7, 24.1, 22.8, 21.1, 16.3, 16.1, 15.9. HRMS (FAB) m/z calcd
for C30H48NO4 [M + H]
+ 486.3577, found 486.3567.
2 - ( ( 4 E , 8 E ) - 1 1 - ( ( R ) - 6 - H y d r o x y - 2 , 8 - d i m e t h y l - 5 -
(morpholinomethyl)chroman-2-yl)-4,8-dimethylundeca-4,8-dien-
1-ylidene)propane-1,3-diol (37). 37 was obtained from 27d (100 mg,
0.24 mmol, 1 equiv), paraformaldehyde, and morpholine (49 mg, 0.48
mmol, 2 equiv) with 95% yield using the same method as described
above for 35. Rf (neutral Al2O3) = 0.40 (DCM/petroleum ether/
MeOH 5:4:1). 1H NMR (500 MHz, acetone-d6) δH 6.41 (s, 1H), 5.47
(t, J = 7.2 Hz, 1H), 5.16 (t, J = 7.2 Hz, 1H), 5.12 (t, J = 7.2 Hz, 1H),
4.17 (s, 2H), 4.10 (s, 2H), 3.66 (t, J = 3.9 Hz, 4H), 3.65 (s, 2H), 2.67
(t, J = 6.8 Hz, 2H), 2.52 (s, 4H), 2.22 (s, 3H), 2.20−2.11 (m, 4H),
2.09−2.06 (m, 2H), 2.07 (s, 3H), 2.01−1.96 (m, 4H), 1.85−1.71 (m,
2H), 1.63−1.49 (m, 2H), 1.59 (s, 6H), 1.23 (s, 3H). 13C NMR (125
MHz, acetone-d6) δC 151.3, 145.4, 140.2, 135.5, 135.3, 127.8, 126.4,
125.5, 125.2, 120.0, 117.0, 116.7, 74.7, 67.3 (2C), 65.9, 58.9, 56.9,
53.6 (2C), 46.1, 40.5, 40.3, 39.7, 32.3, 27.2, 26.7, 24.2, 22.8, 21.1,





propane-1,3-diol (38). 38 was obtained from 27d (100 mg, 0.24
mmol, 1 equiv), paraformaldehyde, and piperidine (47 mg, 0.48
mmol, 2 equiv) with 95% yield using the same method as described
above for 35. Rf (neutral Al2O3) = 0.35 (DCM/petroleum ether/
MeOH 5:4:1). 1H NMR (500 MHz, acetone-d6) δH 6.38 (s, 1H), 5.47
(t, J = 7.2 Hz, 1H), 5.16 (t, J = 7.2 Hz, 1H), 5.12 (t, J = 7.2 Hz, 1H),
4.17 (s, 2H), 4.10 (s, 2H), 3.60 (s, 2H), 2.64 (t, J = 6.8 Hz, 2H),
2.58−2.39 (m, 4H), 2.22 (s, 3H), 2.20−2.11 (m, 4H), 2.09−2.06 (m,
2H), 2.07 (s, 3H), 2.01−1.96 (m, 4H), 1.85−1.71 (m, 2H), 1.63−
1.43 (m, 14H), 1.23 (s, 3H). 13C NMR (125 MHz, acetone-d6) δC
151.8, 145.2, 140.2, 135.5, 135.3, 127.8, 126.2, 125.5, 125.2, 119.7,
117.0, 117.2, 74.7, 66.0, 58.9, 57.5, 54.4 (2C), 46.1, 40.5, 40.3, 39.7,
32.3, 27.2, 26.8, 26.7 (2C), 24.8, 24.2, 22.8, 21.0, 16.3, 16.1, 15.9.





ylidene)propane-1,3-diol (39). 39 was obtained from 27d (100 mg,
0.24 mmol, 1 equiv), paraformaldehyde, and N-methylpiperazine (55
mg, 0.48 mmol, 2 equiv) with 92% yield using the same method as
described above for 35. Rf (neutral Al2O3) = 0.35 (DCM/petroleum
ether/MeOH 5:4.5:0.5). 1H NMR (500 MHz, acetone-d6) δH 6.39 (s,
1H), 5.47 (t, J = 7.2 Hz, 1H), 5.15 (t, J = 7.2 Hz, 1H), 5.12 (t, J = 7.2
Hz, 1H), 4.17 (s, 2H), 4.10 (s, 2H), 3.63 (s, 2H), 2.65 (t, J = 6.8 Hz,
2H), 2.55−2.25 (m, 8H), 2.22 (s, 3H), 2.20−2.11 (m, 4H), 2.09−
2.06 (m, 2H), 2.07 (s, 3H), 2.01−1.96 (m, 4H), 1.85−1.71 (m, 2H),
1.63−1.49 (m, 2H), 1.59 (s, 6H), 1.23 (s, 3H). 13C NMR (125 MHz,
acetone-d6) δC 151.5, 145.2, 140.2, 135.4, 135.3, 127.6, 126.4, 125.5,
125.2, 119.8, 117.0 (2C), 74.7, 65.9, 58.9, 56.7, 55.8 (2C), 53.1 (2C),
46.1, 40.5, 40.3, 39.7, 32.3, 27.2, 26.7, 24.1, 22.8, 21.1, 16.3, 16.1,




methy l t r ideca-3 ,7 ,11- t r ien-1 -y l ) -5 ,7 ,10- t r imethy l -8 ,9 -
dihydropyrano[2,3-g]chromen-2(7H)-one (41). To a solution of
aldehyde 33 (0.11 mmol, 1 equiv) in ethanol (3 mL), piperidine (11
μL, 0.11 mmol, 1 equiv) and ethyl acetoacetate (17 μL, 0.132 mmol,
1.2 equiv) were added. The reaction mixture was refluxed until
completion of the reaction monitored by TLC. After cooling to room
temperature, the reaction mixture was diluted with ether. The organic
layer was washed with water to pH 7 and brine, dried over anhydrous
sodium sulfate, filtered, and concentrated under reduced pressure.
The crude residue was purified by silica preparative TLC to yield the
corresponding coumarine 41 with 89% yield. Rf = 0.35 (petroleum
ether/DCM/acetone 5:3:2). 1H NMR (500 MHz, acetone-d6) δH
8.64 (s, 1H), 5.47 (t, J = 7.2 Hz,1H), 5.18 (t, J = 7.2 Hz,1H), 5.13 (t,
J = 7.2 Hz,1H), 4.16 (d, J = 4.8 Hz, 2H), 4.09 (d, J = 4.8 Hz, 2H),
3.67 (t, J = 5.3 Hz, 1H), 3.59 (t, J = 5.3 Hz, 1H), 2.85 (t, J = 7.0 Hz,
2H), 2.61 (s, 3H), 2.41 (s, 3H), 2.29 (s, 3H), 2.23−2.14 (m, 4H),
2.11−2.06 (m, 2H), 2.01−1.96 (m, 4H), 1.96−1.81 (m, 2H), 1.73−
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1.63 (m, 2H), 1.58 (s, 3H), 1.61 (s, 3H), 1.33 (s, 3H). 13C NMR
(125 MHz, acetone-d6) δC 195.7, 159.7, 149.0, 148.2, 145.1, 140.2,
135.7, 135.3, 129.6, 127.7, 125.2, 125.1, 123.6, 122.9, 122.0, 116.7,
76.9, 65.9, 58.9, 40.4, 40.3, 39.9, 31.5, 30.4, 27.2, 26.6, 24.1, 22.8,
22.1, 16.1, 16.0, 10.8, 10.6. IR (ATR) νmax 3364, 2925, 2855, 1726,





[3,2-f ]chromen-3(8H)-one (42). 42 was obtained from 34 with 93%
yield using the same method as described above for 41. Rf = 0.35
(petroleum ether/DCM/acetone 5:3:2). 1H NMR (500 MHz,
acetone-d6) δH 8.57 (s, 1H), 7.08 (s, 1H), 5.47 (t, J = 7.2 Hz, 1H),
5.18 (t, J = 7.2 Hz, 1H), 5.13 (t, J = 7.2 Hz, 1H), 4.16 (d, J = 4.8 Hz,
2H), 4.09 (d, J = 4.8 Hz, 2H), 3.66 (t, J = 5.3 Hz, 1H), 3.57 (t, J = 5.3
Hz, 1H), 3.09−3.06 (m, 2H), 2.60. (s, 3H), 2.30 (s, 3H), 2.23−2.14
(m, 4H), 2.11−2.06 (m, 2H), 2.01−1.96 (m, 4H), 1.96−1.81 (m,
2H), 1.73−1.63 (m, 2H), 1.61 (s, 3H), 1.58 (s, 3H), 1.35 (s, 3H). 13C
NMR (125 MHz, acetone-d6) δC 196.7, 159.8, 150.7, 149.4, 144.0,
140.2, 136.0, 135.7, 135.3, 127.7, 125.2, 125.1, 123.6, 119.1, 116.6,
116.0, 77.0, 65.9, 58.9, 40.5, 40.4, 39.9, 31.5, 30.4, 27.2, 26.6, 23.9,
22.8, 19.5, 17.2, 16.1, 16.0. HRMS (ESI) m/z calcd for C32H42NaO6
[M + Na]+ 545.2874, found 545.2870.
Ethyl-(R)-8-((3E,7E)-13-hydroxy-12-(hydroxymethyl)-4,8-dime-
thyltrideca-3,7,11-trien-1-yl)-6,8-dimethyl-3-oxo-3,8,9,10-
tetrahydropyrano[3,2-f ]chromene-2-carboxylate (43). 43 was
obtained from 34 and diethyl malonate with 90% yield using the
same method as described above for 41. Rf = 0.30 (petroleum ether/
DCM/acetone, 5:3:2). 1H NMR (500 MHz, acetone-d6) δH 8.63 (s,
1H), 7.05 (s, 1H), 5.45 (t, J = 7.2 Hz,1H), 5.18 (t, J = 7.2 Hz,1H),
5.13 (t, J = 7.2 Hz, 1H), 4.31 (q, J = 7.1 Hz, 2H), 4.16 (d, J = 4.8 Hz,
2H), 4.09 (d, J = 4.8 Hz, 2H), 3.71 (t, J = 5.3 Hz, 1H), 3.63 (t, J = 5.3
Hz, 1H), 3.06 (t, J = 6.3 Hz, 2H), 2.30 (s, 3H), 2.23−2.14 (m, 4H),
2.11−2.06 (m, 2H), 2.01−1.96 (m, 4H), 1.96−1.81 (m, 2H), 1.73−
1.63 (m, 2H), 1.61 (s, 3H), 1.58 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H),
1.35 (s, 3H). 13C NMR (125 MHz, acetone-d6) δC 164.2, 156.9,
150.7, 149.4, 145.2, 140.2, 136.5, 135.7, 135.3, 127.7, 125.2, 125.1,
118.6, 117.4, 116.6, 115.4, 76.9, 65.9, 61.9, 58.9, 40.5, 40.4, 39.9, 31.0,
27.2, 26.6, 23.9, 22.8, 19.4, 17.2, 16.1, 15.9, 14.5. HRMS (ESI) m/z
calcd for C33H44NaO7 [M + Na]
+ 575.2979, found 575.2969.
Ethyl-4-(((2R)-2-((3E,7E)-11-(2-(3,4-dimethoxyphenyl)-1,3-diox-
an-5-ylidene)-4,8-dimethylundeca-3,7-dien-1-yl)-2,8-dimethylchro-
man-6-yl)oxy)butanoate (67). Under a nitrogen atmosphere, a
solution of 44 (1 equiv) in dry THF (0.05 M) was added dropwise to
a suspension of sodium hydride (60% wt, 3 equiv) in 2 mL of dry
THF cooled at 0 °C. After 1 h of stirring at this temperature, 2.4 equiv
of ethyl bromobutyrate was added. The reaction mixture was stirred
further for 3 h. Then, it was diluted with ethyl acetate (15 mL). The
organic layer was washed with water (4 × 15 mL) and brine (15 mL)
and dried over anhydrous sodium sulfate. After filtration and removal
of the solvent under reduced pressure, the crude residue was purified
by silica gel column chromatography eluted with cyclohexane/EtOAc,
leading to 67 with 70% yield. Rf = 0.35 (petroleum ether/DCM 7:3).
1H NMR (500 MHz, acetone-d6) δH 7.02 (d, J = 1.8 Hz, 1H), 6.97 (d,
J = 8.2 Hz, 1H), 6.89 (d, J = 8.2 Hz, 1H), 6.56 (d, J = 3.2 Hz, 1H),
6.46 (d, J = 3.2 Hz, 1H), 5.58 (s, 1H), 5.37 (t, J = 7.2 Hz, 1H), 5.17
(t, J = 7.2 Hz, 1H), 5.15 (t, J = 7.2 Hz, 1H), 4.79 (d, J = 13.0 Hz, 1H),
4.58 (s, 2H), 4.49 (d, J = 13.0 Hz, 1H), 4.34 (d, J = 13.0 Hz, 1H),
4.30 (dd, J = 1.6 Hz, 13.0 Hz, 1H), 4.09 (t, J = 7.2 Hz, 3H), 3.91 (t, J
= 6.2 Hz, 2H), 3.79 (s, 6H), 2.72 (t, J = 6.8 Hz, 2H), 2.46 (t, J = 7.2
Hz, 2H), 2.26−2.05 (m, 11H), 2.03−1.96 (m, 4H), 1.86−1.72 (m,
2H), 1.66−1.52 (m, 2H), 1.60 (s, 6H), 1.27 (s, 3H), 1.24 (t, J = 7.2
Hz, 3H), 1.22 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, acetone-d6)
δC 173.4, 152.5, 150.5, 149.9, 146.7, 136.4, 134.8, 132.7, 131.0, 127.3,
125.8, 125.6, 125.4, 121.7, 119.6, 116.2, 112.6, 111.9, 110.8, 102.2,
75.9, 72.7, 67.7, 66.6, 60.6, 56.0 (2C), 40.3, 40.2, 40.0, 32.1, 31.2,
27.1, 25.8, 25.6, 24.4, 23.1, 22.8, 16.4, 16.1, 15.9, 14.5. HRMS (ESI)
m/z calcd for C40H58NaO8 [M + Na]
+ 713.4024, found 713.4023.
2-(((2R)-2-((3E,7E)-11-(2-(3,4-Dimethoxyphenyl)-1,3-dioxan-5-
ylidene)-4,8-dimethylundeca-3,7-dien-1-yl)-2,8-dimethylchroman-
6-yl)oxy)acetamide (69). 69 was obtained from 44 and bromoace-
tamide with 66% yield after purification through column chromatog-
raphy eluted with petroleum ether/DCM. Rf = 0.30 (ethyl acetate/
cyclohexane 5:5). 1H NMR (500 MHz, acetone-d6) δH 7.08 (bs, 2H),
7.01 (d, J = 1.6 Hz, 1H), 6.96 (dd, J = 1.6 Hz, 8.3 Hz, 1H), 6.89 (d, J
= 8.3 Hz, 1H), 6.63 (d, J = 2.8 Hz, 1H), 6.53 (d, J = 2.8 Hz, 1H), 5.58
(s, 1H), 5.37 (t, J = 7.2 Hz, 1H), 5.17 (t, J = 7.2 Hz, 1H), 5.14 (t, J =
7.2 Hz, 1H), 4.79 (d, J = 13.0 Hz, 1H), 4.48 (d, J = 13.0 Hz, 1H),
4.34 (d, J = 13.0 Hz, 1H), 4.30 (d, J = 13.0 Hz, 1H), 4.31 (s, 2H),
3.79 (s, 6H), 2.73 (t, J = 6.8 Hz, 2H), 2.12 (s, 3H), 2.24−1.96 (m,
10H), 1.88−1.69 (m, 2H), 1.67−1.52 (m, 2H), 1.60 (s, 6H), 1.26 (s,
3H). 13C NMR (125 MHz, acetone-d6) δC 171.2, 151.4, 150.4, 149.9
(2C), 147.4, 135.4, 134.8, 132.7, 131.0, 127.6, 125.8, 125.6, 125.4,
121.9, 119.6, 116.4, 113.4, 111.9, 110.8, 102.2, 76.1, 72.7, 68.5, 66.6,
56.0 (2C), 40.3, 40.2, 40.0, 32.2, 27.2, 25.8, 24.4, 23.1, 22.9, 16.4,





6-yl)oxy)butanoic Acid (45). LiOH (93 μL of a 10% aqueous
solution, 3 equiv) was added to a solution of 67 (90 mg, 0.13 mmol, 1
equiv) in THF (3 mL). The reaction mixture was stirred at room
temperature for 3 h. It was then diluted with water and acidified with
1 N HCl down to pH 4−5. The aqueous layer was extracted with 3 ×
10 mL of EtOAc. The combined organic extracts were washed with
brine, dried over anhydrous sodium sulfate, filtered, and concentrated
to dryness under reduced pressure. 45 was obtained with 85% yield. Rf
= 0.30 (acetone/petroleum ether 4:6). 1H NMR (500 MHz, acetone-
d6) δH 7.02 (d, J = 1.8 Hz, 1H), 6.97 (d, J = 8.2 Hz, 1H), 6.89 (d, J =
8.2 Hz, 1H), 6.56 (d, J = 3.2 Hz, 1H), 6.46 (d, J = 3.2 Hz, 1H), 5.58
(s, 1H), 5.37 (t, J = 7.2 Hz, 1H), 5.17 (t, J = 7.2 Hz, 1H), 5.15 (t, J =
7.2 Hz, 1H), 4.79 (d, J = 13.0 Hz, 1H), 4.58 (s, 2H), 4.49 (d, J = 13.0
Hz, 1H), 4.34 (d, J = 13.0 Hz, 1H), 4.30 (dd, J = 13.0 Hz, 1.6 Hz,
1H), 4.09 (q, J = 7.2 Hz, 2H), 3.92 (t, J = 6.2 Hz, 2H), 3.79 (s, 6H),
2.72 (t, J = 6.8 Hz, 2H), 2.48 (t, J = 7.2 Hz, 2H), 2.26−2.05 (m, 8H),
2.11 (s, 3H), 2.03−1.96 (m, 4H), 1.84−1.66 (m, 2H), 1.66−1.52 (m,
2H), 1.60 (s, 6H), 1.27 (s, 3H). 13C NMR (125 MHz, acetone-d6) δC
174.4, 152.5, 150.4, 149.8, 146.7, 135.4, 134.8, 132.7, 131.0, 127.3,
125.7, 125.6, 125.4, 121.7, 119.6, 116.2, 112.7, 111.8, 110.7, 102.2,
75.9, 72.7, 67.7, 66.5, 56.0, 55.9, 40.3, 40.2, 40.0, 32.1, 30.8, 27.5,
27.1, 25.8, 25.6, 24.4, 23.1, 22.8, 16.4, 16.1, 15.9. HRMS (ESI) m/z
calcd for C40H54NaO8 [M + Na]
+ 685.3711, found 685.3710
(2R)-2-((3E,7E)-4,8-Dimethyl-11-(2-(4-nitrophenyl)-1,3-dioxan-5-
ylidene)undeca-3,7-dien-1-yl)-2,8-dimethylchroman-6-ol (70). To a
stirred solution of 27d (216 mg, 0.5 mmol) in dry THF (5 mL) were
added pTSA (22 mg, 0.12 mmol, 0.23 equiv) and a solution of 4-
nitrobenzaldehyde dimethyl acetal (198 mg, 1 mmol, 2 equiv) in dry
THF (5 mL). The reaction mixture was refluxed for 5 h. The reaction
mixture was cooled down to room temperature, and EtOAc (30 mL)
was added. The organic layer was washed with a saturated aqueous
solution of NaHCO3 (20 mL) and brine (20 mL), dried over Na2SO4,
and evaporated to dryness. Purification by column chromatography
on silica gel and eluting with a petroleum ether/acetone (PE/
acetone) mixture afforded the desired protected product 70 with 78%
yield. Rf = 0.3 (petroleum ether/acetone 85:15).
1H NMR (500 MHz,
acetone-d6) δH 8.24 (d, J = 8.9 Hz, 2H), 7.73 (d, J = 8.9 Hz, 2H), 7.44
(s, 1H), 6.46 (d, J = 2.8 Hz, 1H), 6.36 (d, J = 2.8 Hz, 1H), 5.82 (s,
1H), 5.43 (t, J = 7.2 Hz,1H), 5.17 (t, J = 7.2 Hz, 1H), 5.14 (t, J = 7.2
Hz, 1H), 4.87 (d, J = 13.0 Hz, 1H), 4.58 (d, J = 13.0 Hz, 1H), 4.44.
(d, J = 13.0 Hz, 1H), 4.38 (d, J = 13.0 Hz, 1H), 2.67 (t, J = 6.8 Hz,
2H), 2.09 (s, 3H), 2.24−2.07 (m, 6H), 2.03−1.96 (m, 4H), 1.88−
1.69 (m, 2H), 1.67−1.52 (m, 2H), 1.60 (s, 6H), 1.27 (s, 3H). 13C
NMR (125 MHz, acetone-d6) δC 150.4, 148.8, 146.3, 145.6, 135.2,
134.6, 130.2, 128.2 (2C), 127.1, 126.4, 125.6, 125.2, 123.9 (2C),
121.6, 116.3, 113.3, 100.3, 75.7, 72.7, 66.6, 40.2, 40.1, 39.8, 32.0, 27.0,
25.7, 24.2, 22.9, 22.7, 16.1, 15.9, 15.7. HRMS (FAB) m/z calcd for
C34H43NNaO6 [M + Na]
+ 584.2983, found 584.2974.
(2R)-2-((3E,7E)-4,8-Dimethyl-11-(2-(4-nitrophenyl)-1,3-dioxan-5-
ylidene)undeca-3,7-dien-1-yl)-5-(hydroxymethyl)-2,8-dimethyl-
chroman-6-ol (48). In a two-neck round-bottom flask under a
nitrogen atmosphere, acetic acid (4 μL, 0.05 mmol, 0.6 equiv), boric
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acid (17 mg, 0.27 mmol, 3 equiv), and paraformaldehyde (48 mg,
2.62 mmol, 36 equiv) were added to a solution of the acetal 70 (50
mg, 0.09 mmol, 1 equiv) in 5 mL of dry toluene. The reaction mixture
was refluxed for 12 h. After cooling at room temperature, it was
diluted with toluene (20 mL). The organic layer was washed with
water (20 mL) and then stirred for 30 min with a 5% aqueous
solution of sodium carbonate. The organic layer was washed further
with water (15 mL) and brine (15 mL), dried over anhydrous sodium
sulfate, and filtered. After removal of the solvent under reduced
pressure, the crude product was purified using preparative TLC eluted
with a mixture of petroleum ether/acetone/dichloromethane (8:2:1),
leading to 48 with 55% yield (33 mg). Rf = 0.30 (petroleum ether/
acetone 8:2). 1H NMR (400 MHz, acetone-d6) δH 8.25 (d, J = 8.8 Hz,
2H), 8.02 (s, 1H), 7.73 (d, J = 8.8 Hz, 2H), 6.48 (s, 1H), 5.82 (s,
1H), 5.43 (t, J = 7.2 Hz, 1H), 5.17−5.14 (m, 2H), 4.87 (d, J = 13.0
Hz, 1H), 4.74 (d, J = 4.5 Hz, 2H), 4.57 (d, J = 13.0 Hz, 1H), 4.44. (d,
J = 13.0 Hz, 1H), 4.38 (d, J = 13.0 Hz, 1H), 4.26−4.23 (m, 1H), 2.73
(t, J = 6.8 Hz, 2H), 2.11 (s, 3H), 2.26−2.09 (m, 9H), 2.03−1.96 (m,
4H), 1.88−1.73 (m, 2H), 1.67−1.52 (m, 2H), 1.61 (s, 3H) 1.60 (s,
3H), 1.24 (s, 3H). 13C NMR (100 MHz, acetone-d6) δC 149.5, 149.0,
146.5, 145.6, 135.4, 134.8, 130.4, 128.4 (2C), 126.6, 126.4, 125.7,
125.5, 124.0 (2C), 120.2, 116.8, 100.5, 74.9, 72.9, 66.8, 58.4, 40.3
(2C), 40.0, 39.9, 32.1, 27.2, 25.8, 24.1, 22.9, 20.2, 16.3, 16.0, 15.9.





trimethylchroman-6-ol (46). To a stirred solution of 64 (152 mg,
0.25 mmol) in dry THF (20 mL) were added magnesium chloride
(238 mg, 10 equiv), paraformaldehyde (249 mg, 32 equiv), and
triethylamine (1.18 mL, 32 equiv) at room temperature. The mixture
was stirred under reflux for 2 h. The heterogeneous mixture was
cooled down to room temperature, and 1 N HCl (10 mL) and Et2O
(30 mL) were added dropwise. The organic layer was separated, and
the aqueous layer was extracted with Et2O (2 × 10 mL). The
combined organic extracts were washed with brine (20 mL), dried
over Na2SO4, and evaporated to dryness. Purification by column
chromatography on silica gel, using a petroleum ether/acetone/DCM
(7:2:1) mixture as the mobile phase, afforded 46 (33% yield) along
with the desired formylated product 47 with 36% yield. Rf = 0.68
(petroleum ether/acetone/DCM 7:2:1). Pale-yellow oil; 1H NMR
(500 MHz, acetone-d6) δH 8.25 (s, 1H, OH), 7.02 (d, J = 1.8 Hz,
1H), 6.98 (dd, J = 1.8 Hz, 8.2 Hz, 1H), 6.89 (d, J = 8.2 Hz, 1H), 5.58
(s, 1H), 5.36 (t, J = 7.2 Hz, 1H), 5.16 (t, J = 7.2 Hz, 1H), 5.14 (t, J =
7.2 Hz, 1H), 4.92 (t, J = 4.5 Hz, 1H), 4.85 (d, J = 5.0 Hz, 2H), 4.79
(d, J = 13.0 Hz, 1H), 4.48 (d, J = 13.0 Hz, 1H), 4.33 (d, J = 13.0 Hz,
1H), 4.31 (d, J = 13.0 Hz, 1H), 3.79 (s, 3H), 3.78 (s, 3H), 2.60 (t, J =
6.8 Hz, 2H), 2.05 (s, 6H), 2.24−2.06 (m, 6H), 2.04−1.97 (m, 6H, H-
17), 1.86−1.71 (m, 2H), 1.66−1.48 (m, 2H), 1,60 (s, 6H), 1.23 (s,
3H). 13C NMR (125 MHz, acetone-d6) δC 150.5, 149.9 (2C), 148.5,
145.2, 135.5, 134.8, 132.7, 131.0, 125.8, 125.6, 125.5, 122.9, 120.8,
120.8, 120.1, 119.6, 111.9, 110.8, 102.2, 74.8, 72.7, 66.6, 60.9, 56.0
(2C), 40.3, 40.0 (2C), 32.3, 27.1, 25.8, 24.1, 22.9, 21.3, 16.0, 15.9,





6-yl)oxy)-4-oxobutanoic Acid (68). Under a nitrogen atmosphere,
succinic anhydride (175 mg, 1.79 mmol, 10.3 equiv) and triethyl-
amine (244 μL, 1.79 mmol, 10.3 equiv) were added to a dry THF
solution (4 mL) of acetal 64 (100 mg, 174 mmol, 1.0 equiv). The
reaction mixture was stirred at room temperature for 20 h. It was then
diluted with water and acidified to pH 4 with 1 N HCl. The aqueous
layer was extracted three times with ethyl acetate (3 × 15 mL). The
combined organic layers were washed once with water and brine,
dried over sodium sulfate, filtered, and concentrated under reduced
pressure to yield 135 mg of 68 as an oil. The product was used
without further purification. Rf = 0.30 (petroleum ether/acetone 3:7).
1H NMR (400 MHz, acetone-d6) δH 7.02 (d, J = 1.8 Hz, 1H), 6.97 (d,
J = 8.2 Hz, 1H), 6.89 (d, J = 8.2 Hz, 1H), 6.68 (d, J = 3.2 Hz, 1H),
6.63 (d, J = 3.2 Hz, 1H), 5.58 (s, 1H), 5.37 (t, J = 7.2 Hz, 1H), 5.18
(t, J = 7.2 Hz, 1H), 5.15 (t, J = 7.2 Hz, 1H), 4.79 (d, J = 13.0 Hz, 1H),
4.49 (d, J = 13.0 Hz, 1H), 4.34 (d, J = 13.0 Hz, 1H), 4.30 (dd, J =
13.0 Hz, 1.6 Hz, 1H), 3.79 (s, 6H), 2.80 (t, J = 7.2 Hz, 2H), 2.75 (t, J
= 7.2 Hz, 2H), 2.70 (t, J = 6.2 Hz, 2H), 2.25−2.08 (m, 6H), 2.13 (s,
3H), 2.03−1.96 (m, 4H), 1.90−1.72 (m, 2H), 1.68−1.52 (m, 2H),
1.61 (s, 6H), 1.29 (s, 3H). 13C NMR (100 MHz, acetone-d6) δC
173.8, 172.1, 150.4, 149.8 (2C), 150.2, 143.9, 135.4, 134.8, 132.7,
131.0, 127.3, 125.8, 125.6, 125.4, 122.1, 121.1, 120.2, 119.6, 111.8,
110.7, 102.2, 76.6, 72.7, 66.6, 56.0 (2C), 40.3 (2C), 40.0, 31.7, 29.5,
29.2, 27.1, 25.6, 24.4, 24.3, 22.8, 16.2, 16.1, 15.9. HRMS (FAB) m/z
calcd for C40H53O9 [M + H]
+ 677.3684, found 677.3674.
4-(((R)-2-((3E,7E)-13-Hydroxy-12-(hydroxymethyl)-4,8-dimethyl-
trideca-3,7,11-trien-1-yl)-2,8-dimethylchroman-6-yl)oxy)-4-oxobu-
tanoic Acid (31). para-Toluenesulfonic acid (1.15 equiv) was added
to a solution of acetal 68 (1 equiv) in THF (0.05 M). The reaction
mixture was stirred at room temperature for 1 h and was diluted with
EtOAc. The organic layer was washed twice with a saturated aqueous
solution of NaHCO3, twice with water, and once with brine. It was
then dried over anhydrous sodium sulfate, filtered, and concentrated
under reduced pressure. The crude residue was purified by C18 flash
chromatography using a water/MeOH gradient leading to 31 with
60% yield. 1H NMR (400 MHz, acetone-d6) δH 6.68 (d, J = 3.2 Hz,
1H), 6.63 (d, J = 3.2 Hz, 1H), 5.47 (t, J = 7.2 Hz, 1H), 5.18−5.14 (m,
2H), 4.17 (s, 2H), 4.09 (s, 2H), 2.85−2.72 (m, 4H), 2.71−2.68 (m,
2H), 2.21−2.08 (m, 6H), 2.13 (s, 3H), 2.03−1.96 (m, 4H), 1.90−
1.75 (m, 2H), 1.68−1.52 (m, 2H), 1.61 (s, 3H), 1.59 (s, 3H), 1.29 (s,
3H). 13C NMR (100 MHz, acetone-d6) δC 173.6, 172.0, 150.2, 143.9,
140.1, 135.6, 135.3, 127.7, 127.3, 125.2, 122.1, 121.8, 120.2, 76.6,
65.9, 58.9, 40.5, 40.4, 40.3 (2C), 31.7, 29.7, 29.2, 27.2, 26.6, 24.4, 22.8
(2C), 16.2, 16.1, 15.9. IR (ATR) νmax 3425, 2972, 2901, 1696, 1406,
1380, 1225, 1057, 835 cm−1. HRMS (FAB) m/z calcd for C31H43O7
[M − H]− 527.3003, found 527.3008.
2-(((R)-2-((3E,7E)-13-Hydroxy-12-(hydroxymethyl)-4,8-dimethyl-
trideca-3,7,11-trien-1-yl)-2,8-dimethylchroman-6-yl)oxy)acetamide
(32). 32 was obtained from 69 with 72% yield using the method
described above for 31 after purification by preparative TLC using a
mixture of DCM/EtOAc/MeOH (70:30:7) as the mobile phase. Rf =
0.30 (cyclohexane/ethyl acetate 6:4). 1H NMR (500 MHz, acetone-
d6) δH 7.08 (bs, 1H), 6.68 (bs, 1H), 6.63 (d, J = 2.8 Hz, 1H), 6.53 (d,
J = 2.8 Hz, 1H), 5.46 (t, J = 7.2 Hz, 1H), 5.18 (t, J = 7.2 Hz, 1H),
5.14 (t, J = 7.2 Hz, 1H), 4.31 (s, 2H), 4.17 (d, J = 5.5 Hz, 2H), 4.10
(d, J = 5.5 Hz, 2H), 3.65 (t, J = 5.2 Hz, 1H), 3.57 (t, J = 5.2 Hz, 1H),
2.74 (t, J = 6.8 Hz, 2H), 2.23−2.12 (m, 4H), 2.12 (s, 3H), 2.11−2.06
(m, 2H), 2.01−1.96 (m, 4H), 1.90−1.70 (m, 2H), 1.65−1.55 (m,
2H), 1.58 (s, 3H), 1.61 (s, 3H), 1.31 (s, 3H). 13C NMR (125 MHz,
acetone-d6) δC 171.2, 151.5, 147.4, 140.2, 135.6, 135.3, 127.6, 127.5,
125.3, 125.2, 121.9, 116.4, 113.0, 76.1, 68.5, 65.9, 58.8, 40.5, 40.4,
40.1, 32.1, 27.2, 26.6, 24.4, 23.1, 22.8, 16.4, 16.1, 15.9. HRMS (ESI)
m/z calcd for C29H43NNaO5 [M + Na]
+ 508.3034, found 508.3032.
Analysis of Pan Assay Interference Compounds (PAINS). All
investigated compounds were examined for known classes of assay
interference compounds using the bulk pattern checker of ZINC15
(http://zinc15.docking.org/patterns/home/). Compounds 23, 24,
and 35−40 were detected as Mannich bases. They effectively
inhibited 5-LOX in a cell-free assay, with a few exceptions (24, 40),
but were considerably less active in suppressing 5-LOX product
formation in PMNL and therefore were not further investigated.
5-LOX Activity. Human recombinant 5-LOX was expressed in E.
coli Bl21 (DE3) cells that were transformed with pT3−5LOX (wt 5-
LOX), 5-LOX_3W (triple mutation of Trp102Ala/Trp13Ala/
Trp75Ala), or 5-LOX_R (single mutant of the Arg101Asp plasmid)
and purified on an ATP-agarose column (Econo-Pac, Bio-Rad,
Hercules, CA) by affinity chromatography.6,75 In a first step, E. coli
was lysed in 50 mM triethanolamine/HCl pH 8.0 with EDTA (5
mM), soybean trypsin inhibitor (60 μg/mL), phenylmethylsulfonyl
fluoride (1 mM), dithiothreitol (1 mM), and lysozyme (1 mg/mL)
and sonified three times for 15 s. The homogenate was centrifuged at
10 000g for 15 min, followed by centrifugation of the supernatant at
40 000g for 70 min at 4 °C. The supernatant was transferred to an
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ATP-agarose column (Sigma-Aldrich, Deisenhofen, Germany), which
was sequentially washed with PBS pH 7.4, 1 mM EDTA, 50 mM
phosphate buffer pH 7.4, 0.5 M NaCl, 1 mM EDTA, and finally 50
mM phosphate buffer pH 7.4 plus 1 mM EDTA. The enzyme was
eluted with 50 mM phosphate buffer pH 7.4, 50 mM EDTA, and 20
mM ATP.
Purified 5-LOX (0.5 μg in PBS pH 7.4 containing 1 mM EDTA
and 1 mM ATP) was preincubated with the vehicle (DMSO) or test
compounds for 10 min and prewarmed at 37 °C. 5-LOX product
formation was started by addition of arachidonic acid (Sigma-Aldrich;
20 μM or as indicated) and CaCl2 (2 mM) and stopped by an equal
volume of ice-cold methanol after 10 min at 37 °C. Major 5-LOX
metabolites (all-trans isomers of LTB4 and 5-HETE) were extracted
on Sep-Pak C18 35 cc Vac Cartridges (Waters, Milford, MA),
separated by RP-HPLC on a Nova-Pak C18 Radial-Pak column (4
μm, 5 mm × 100 mm, Waters) under isocratic conditions (73%
methanol/27% water/0.007% trifluoroacetic acid) at a flow rate of 1.2
mL/min, and detected at 235 and 280 nm.75 Zileuton was used as the
reference 5-LOX inhibitor. To investigate whether 27a reversibly
inhibits 5-LOX, the purified enzyme was preincubated with 27a at 0.3
μM for 15 min. The reaction mix was then 10-fold diluted to a final
compound concentration of 0.03 μM, and arachidonic acid (20 μM)
and CaCl2 (1 mM) were added after another 5 min incubation on ice.
To recognize nuisance inhibition, Triton X-100 (Sigma-Aldrich;
0.01%) was added to the reaction buffer.
Radical Scavenging Activity. Compound 27a was incubated
with 2,2-diphenyl-1-picrylhydrazyl (DPPH, Sigma-Aldrich; 50 mM)
in ethanol for 30 min, and the absorbance was measured at 520 nm
using a Multiskan Spectrum Microplate Reader (Thermo Fisher
Scientific).72 The positive control ascorbic acid (Sigma-Aldrich; 25
μM) scavenged DPPH radicals by 36 ± 11%.
Human Whole Blood and Blood Cells. Human PMNL, PBMC,
monocytes, and platelets were freshly isolated from leukocyte
concentrates that we obtained together with human whole blood
(containing 3.13% sodium citrate) from the Institute for Transfusion
Medicine of the University Hospital Jena (Germany).76 Venous blood
was collected in heparinized tubes (16 U heparin/mL blood), with
informed consent of registered male and female healthy adult
volunteers (18−65 years) who were fasted for at least 12 h. These
volunteers regularly donated blood (every 8−12 weeks) and were
physically inspected by a clinician. They had not taken antibiotics or
anti-inflammatory drugs for more than 10 days before blood donation
and were free of apparent infections, inflammatory disorders, or acute
allergic reactions.
Leukocytes were concentrated by centrifugation (4000g/20 min/
20 °C) of freshly withdrawn blood and subjected to density gradient
centrifugation on a lymphocyte separation medium (LSM 1077, GE
Healthcare, Freiburg, Germany). Erythrocytes were removed by
dextran sedimentation and hypotonic lysis. PMNL were obtained
from the cell pellet and platelets from the supernatant. The PBMC
fraction was plated in cell culture flasks (Greiner, Nuertingen,
Germany) for 1.5 h at 37 °C and 5% CO2 in an RPMI 1640 medium
(Sigma-Aldrich) with 5% FCS (Sigma-Aldrich), 2 mM L-glutamine
(Sigma-Aldrich), and penicillin (100 U/mL)/streptomycin (100 μg/
mL, GE Healthcare) (monocyte medium) to isolate adherent
monocytes. The purity of monocytes (>85%) was determined from
forward and side scatter properties, and CD14 surface expression was
determined by flow cytometry (BD FACS Calibur, Heidelberg,
Germany).
Monocytes were differentiated to macrophages by treatment with
GM-CSF (20 ng/mL) for 6 days in an RPMI 1640 medium with 10%
FCS, 2 mM L-glutamine, and penicillin (100 U/mL)/streptomycin
(100 μg/mL). Macrophages were polarized to the M1 phenotype by
stimulation with LPS (100 ng/mL, Sigma-Aldrich) and interferon
(IFN)-γ (20 ng/mL, Peprotech, Hamburg, Germany) for 48 h.23
Experiments with blood and blood cells were approved by the
ethics committee of the Friedrich-Schiller-University Jena.
5-LOX Product Formation by PMNL and Blood. Freshly
isolated PMNL (5 × 106) suspended in PBS pH 7.4 with 1 mg/mL
glucose or freshly withdrawn human whole blood were preincubated
with the test compounds for 10 min (or as indicated) at 37 °C. 5-
LOX product formation in PMNL was triggered by addition of
arachidonic acid (20 μM) and/or Ca2+-ionophore A23187 (2.5 μM;
Sigma-Aldrich) followed by incubation for 10 min at 37 °C. The
reaction was stopped with an equal volume of methanol.
Blood was treated with Ca2+-ionophore A23187 (30 μM) for 10
min at 37 °C or was first primed for 30 min with LPS (1 μg/mL) and
then stimulated with fMLP (1 μM; Sigma-Aldrich) for 15 min. After
the reaction was stopped on ice, plasma was prepared (600g, 10 min,
4 °C), and aliquots were mixed with an equal volume of methanol.
Proteins were precipitated at −20 °C for 2 h and removed by
centrifugation (600g, 15 min, 4 °C).
Major 5-LOX metabolites (all-trans isomers of LTB4 and 5-HETE)
and, for PMNL, additionally 12-HETE (major 12-LOX product) and
15-HETE (major 15-LOX product) were extracted and analyzed by
RP-HPLC as described for the determination of cell-free 5-LOX
activity. Zileuton (3 μM) was used as the reference 5-LOX inhibitor.
Fluorescence Spectroscopy of 5-LOX. Fluorescence spectros-
copy measurements on human recombinant 5-LOX (Abcam,
Cambridge, U.K.) were conducted in PBS pH 7.4 at 25 °C using
an Edinburgh Instruments FLS920 Series fluorescence spectropho-
tometer (Livingston, U.K.). The effect of the ligand concentration was
followed by means of tryptophan fluorescence, with excitation at 295
nm and emission collected between 310 and 450 nm, using excitation
and emission slits of 5 and 10 nm, respectively. The concentration
range of 5-LOX used through the experiments was 0.3−0.6 μM. 5-
LOX was titrated with a stock solution of the test compounds in
dimethylformamide to yield an experimental compound concen-
tration in the range of 0−10 μM. The final dimethylformamide
concentration was kept under 5%. After each addition, the sample was
incubated for 10 min before measurement. The fluorescence emission
intensity values were corrected for dilution and background noise. All
conditions were measured independently and in duplicate.
The fluorescence emission spectral shift was used to monitor
ligand−protein binding since significant variations of intensity were
not observed. The fluorescence spectral shifts were analyzed by
monitoring the alterations in the spectral center of mass by estimating
the intensity-averaged emission wavelength (⟨λ⟩), as calculated from
the following equation, where Fi is the fluorescence emission intensity
at wavenumber νi, and the summation was performed over the range
























Molecular Docking Simulations. The molecular docking
simulation was conducted with GOLD 2020.2.0 (CCDC, Cambridge,
U.K.).77 The built-in CHEMPLP scoring function was used to rescore
the outputted poses (10 best-scored poses were kept for each
compound). The stable crystallographic tridimensional structure of 5-
LOX was downloaded from the Protein Data Bank (PDB entry
3O8Y).78 Four in silico mutations were inserted to return to the 5-
LOX wild-type sequence: E13W, H14F, G75W, and S76L. The
residues were exchanged, and the structure was energetically
minimized in Discovery Studio 3.5 (Biovia, San Diego, CA).79
Hydrogen atoms were added with GOLD, using default settings. The
binding site was constituted by 11 amino acid residues: Gln15,
Arg101, Tyr81, Tyr100, Arg101, Trp102, Val110, Glu134, Asp170,
Arg401, and Glu 622. Hydrogen-bond constraints were applied to
Trp102-Hε1, Val110-HN, Glu134-Oε1, Asp170-Oδ1, Arg401-HH2,
and Arg401-Hε with the constraint weight varying from 7 to 40 and
the minimum H-bond geometry weight at 0.005. The ligands were
allowed to detect internal H-bonds, flip pyramidal N, and flip amide
bonds. Protein−ligand interactions of docking poses were analyzed
using LigandScout 4.3 (Inteligand, Vienna, AT).80
Intracellular Concentrations of 12a and 27a. PMNL (1 ×
107/mL) were suspended in PBS pH 7.4 with 1 mg/mL glucose and
incubated with a vehicle (DMSO, 0.1%), 27a or 12a (150 nM, each)
for 20 min at 37 °C. Cells were centrifuged (1200g, 5 min, 4 °C) and
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washed thrice with PBS pH 7.4 with 0.1% fatty-acid-free BSA (Sigma-
Aldrich). Compounds were extracted and analyzed by UPLC-MS/MS
as described below for LCMs and derivatives. The intracellular
concentrations of 27a and 12a were calculated assuming a spherical
cell shape with a diameter of 13 μm (as measured using a Vi-CELL
Series Cell Counter, Beckman Coulter, Krefeld, Germany) and an
equal intracellular distribution. 13d (9 pmol) was used as the internal
standard.
Monocyte and PBMC Viability. Monocytes (4 × 105/mL) or
PBMC (2 × 106/mL) in a monocyte medium were treated with the
vehicle (0.1% DMSO) and test compounds for 2 or 24 h at 37 °C and
5% CO2. To measure mitochondrial dehydrogenase activity, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (20
μL, 5 mg/mL, Sigma-Aldrich) was added to PBMC. After 4 h in the
darkness, the formed formazan product was solubilized (10% SDS in
20 mM HCl) and the absorbance was read at 570 nm using a
Multiskan Spectrum microplate reader (Thermo Fisher Scientific).81
Staurosporine (3 μM; Merck Chemicals) was used as the cytotoxic
reference compound.
LDH release was measured in monocytes using a CytoTox 96
nonradioactive cytotoxicity assay (Promega, Madison, WI) according
to the manufacturer’s instruction using Triton X-100 (0.8%) as the
maximum LDH release control.
Intracellular Ca2+ Influx. PMNL (1 × 106) were loaded with
Fura-2/AM (2 nmol, Thermo Fisher Scientific) for 45 min at 37 °C.
Washed cells in PBS pH 7.4 with 1 mg/mL glucose were preincubated
with a vehicle (0.1% DMSO) or 27a for 10 min prior to addition of 1
mM Ca2+ and stimulation with 1 μM fMLP for 10 min. Intracellular
Ca2+ concentrations were measured using a NOVOstar fluorescence
microplate reader (BMG Labtech, Ortenberg, Germany) at 37 °C.
The emission wavelength was set to 510 nm and the excitation
wavelengths to 340 nm (Ca2+-bound Fura-2) and 380 nm (free Fura-
2).23 To define 100% Ca2+ influx, the difference between the maximal
influx (cell lysis by Triton X-100) and minimal influx (subsequent
chelation of Ca2+ by EDTA) was measured for each experiment.
mPGES-1 Activity. Human lung carcinoma A549 cells (ATCC,
Manassas, VA) were cultivated in DMEM (high glucose, 4.5 g/L; GE
Healthcare) with 10% FCS and penicillin (100 U/mL)/streptomycin
(100 μg/mL) at 37 °C and 5% CO2. Confluent cells were detached by
trypsin-EDTA (GE Healthcare) and reseeded at a density of 1 × 104
cells/cm2.
A549 cells were treated with IL-1β (2 ng/mL) at 37 °C and 5%
CO2 for 48 h to induce mPGES-1 expression.
81 Cell pellets of
harvested cells were frozen in liquid nitrogen and then incubated on
ice for 15 min and homogenized in ice-cold homogenization buffer
(0.1 M potassium phosphate buffer pH 7.4, 1 mM phenyl-
methanesulfonyl fluoride (PMSF), 60 μg/mL soybean trypsin
inhibitor (STI), 1 μg/mL leupeptin, 2.5 mM glutathione, and 250
mM sucrose) by sonication (3 × 20 s, 4 °C). Differential
centrifugation at 10 000g for 10 min and 174 000g for 1 h at 4 °C
yielded the microsomal fraction. The pellet was resuspended in
homogenization buffer and diluted in 0.1 M potassium phosphate
buffer pH 7.4 containing 2.5 mM glutathione. Microsomal
membranes (adjusted to 2.5−5 μg total protein) were preincubated
with 27a for 15 min at 4 °C. The mPGES-1 substrate PGH2 (20 μM)
was added to induce PGE2 formation. The reaction was stopped after
1 min by addition of an equal volume of aqueous 40 mM FeCl2, 80
mM citric acid, and 1 nmol 11β-PGE2 (Cayman Chemicals) as the
internal standard. PGE2 was extracted on Sep-Pak C18 35 cc Vac
Cartridges (Waters) and separated on a Nova-Pak C18 Radial-Pak
Column (4 μm, 5 mm × 100 mm, Waters) under isocratic conditions
(30% acetonitrile/70% H2O/0.007% trifluoroacetic acid) at a flow
rate of 1 mL/min and detection at 195 nm.82 The mPGES-1 inhibitor
MK-886 (10 μM) was used as the control.
COX-1 and COX-2 Activity. Purified ovine COX-1 (Cayman
Chemicals; 50 units) or human recombinant COX-2 (Cayman
Chemicals; 20 units) was dissolved in 100 mM Tris buffer pH 8, 5
mM glutathione, 5 μM hemoglobin, and 100 μM EDTA. COX
isoenzymes were preincubated with the vehicle (DMSO) or 27a for 5
min at 4 °C and 1 min at 37 °C. Addition of arachidonic acid (COX-
1: 5 μM; COX-2: 2 μM) initiated the formation of COX-derived
12(S)-hydroxy-5-cis-8,10-trans-heptadecatrienoic acid (12-HHT),
which was extracted and analyzed by RP-HPLC according to 5-
LOX products. The COX-1/2 inhibitor indomethacin (10 μM,
Sigma-Aldrich) was used as the control.
Platelet COX-1 Activity. Freshly isolated platelets (1 × 108) were
preincubated with vehicle (DMSO) or 27a for 5 min at room
temperature. Arachidonic acid (5 μM) was added to induce 12-HHT
formation. After incubation for 5 min at 37 °C, 12-HHT was
extracted and analyzed by RP-HPLC as described for 5-LOX
products. The COX-1/2 inhibitor indomethacin (10 μM) was used
as the reference compound.
sEH Activity. Human recombinant sEH was expressed in Sf9
insect cells and purified by affinity chromatography.83 Briefly, Sf9 cells
were infected with a recombinant baculovirus and lysed after 72 h in
50 mM NaHPO4 pH 8, 300 mM NaCl, 10% glycerol, 1 mM EDTA, 1
mM phenylmethanesulfonyl fluoride, 10 μg/mL leupeptin, and 60
μg/mL STI by sonication (3 × 10 s, 4 °C). Sequential centrifugation
at 20 000g (10 min, 4 °C) and 100 000g (60 min, 4 °C) yielded a
supernatant, which was subjected to benzylthio-sepharose affinity
chromatography. Elution with 4-fluorochalcone oxide in PBS pH 7.4
with 1 mM dithiothreitol and 1 mM EDTA yielded sEH, which was
dialyzed and concentrated.
Purified sEH (60 ng) in 25 mM Tris HCl pH 7 with 0.1 mg/mL
bovine serum albumin (BSA) was preincubated with the vehicle
(DMSO) or 27a for 10 min at room temperature. The sEH substrate
PHOME (50 μM, Cayman Chemicals) was added to start the
enzymatic reaction, which was stopped after 60 min in darkness by
addition of ZnSO4 (200 mM). The formation of the fluorescent
product 6-methoxynaphtaldehyde was measured using a NOVOstar
fluorescence microplate reader (BMG Labtech, Ortenberg, Germany),
with excitation at 330 and emission at 465 nm. The selective sEH
inhibitor AUDA (100 nM, Cayman Chemicals) was used as the
control.
Lipid Mediator Extraction for UPLC-MS/MS. Monocytes (1 ×
106/mL), which were prestimulated with LPS (1 μg/mL) for 24 h to
induce COX-2 expression, or M1 macrophages (2 × 106 cells/mL)
were preincubated with the vehicle (0.1% DMSO), 27a, or 12a for 15
min. Arachidonic acid (20 μM) and A23187 (2.5 μM) were added to
monocytes suspended in a monocyte medium (lacking FCS if
indicated) to induce lipid mediator formation.81 Macrophages were
stimulated in PBS pH 7.4 (containing 1 mM CaCl2) with E. coli
(serotype O6:K2:H1) at a ratio of 1:50 (macrophages: E. coli) for 180
min at 37 °C and 5% CO2.
24
Ice-cold methanol was added to monocytes, proteins were
precipitated at −20 °C, and samples were acidified (pH 3.5).81
Lipid mediators were extracted by solid-phase extraction on Sep-Pak
C18 35 cc Vac Cartridges (Waters). After washing with H2O twice,
lipid mediators were eluted with methanol and analyzed by UPLC-
MS/MS.81 PGB1 (100 ng, Cayman Chemicals) was used as the
internal standard.
Fatty acids and lipid mediators were extracted from macrophage
supernatants or murine peritoneal exudates (1 mL) after addition of
two aliquots of ice-cold methanol.23 d8-5S-HETE, d4-LTB4, d5-lipoxin
A4, d5-resolvin D2, d4-PGE2 (200 nM, each, Cayman Chemicals), and
d8-arachidonic acid (10 μM, Cayman Chemicals) were added as
internal standards. After protein precipitation at −20 °C for ≥1 h,
supernatants (1200g, 10 min, 4 °C) were acidified (pH 3.5) and
loaded onto solid-phase cartridges (Sep-Pak Vac 6cc 500 mg/6 mL
C18; Waters), which had been equilibrated with methanol and H2O.
The columns were extensively washed with H2O and hexane before
lipid mediators were eluted with methyl formate, evaporated to
dryness, dissolved in methanol/H2O (50:50), and analyzed by UPLC-
MS/MS.23
Extraction of LCMs and Derivatives. LCMs, 27a, and 27a
metabolites were extracted from PMNL, medium of the liver-on-chip,
murine plasma, peritoneal exudate, or homogenized murine tissue as
described.6 In brief, PBS pH 7.4, methanol, chloroform, and saline
(final ratio: 14:34:35:17) were successively added together with 13d
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(9 pmol) as the internal standard. The organic layer was evaporated,
and the extracted LCMs were dissolved in methanol.
Liquid Chromatography and Mass Spectrometry. Lipid
mediators, LCMs, 27a, and 27a metabolites were separated on an
Acquity UPLC BEH C18 column (1.7 μm, lipid mediators for
monocytes and LCMs: 2.1 mm × 50 mm; otherwise, 2.1 mm × 100
mm, Waters) using an Acquity UPLC system (Waters), which was
coupled to a QTRAP 5500 mass spectrometer (SCIEX, Framingham,
MA) equipped with an electrospray ionization source.6,23,81
Diagnostic ion fragments were detected by (scheduled) multiple
reaction monitoring (MRM) in the negative ion mode.
To analyze lipid mediators produced by monocytes, a flow rate of
0.8 mL/min and a column temperature of 45 °C were applied. Mobile
phase A consisted of acetonitrile with 0.07% formic acid, and mobile
phase B was acetonitrile/H2O (10:90) with 0.07% formic acid.
Isocratic elution at A/B (30:70) for 2 min was followed by a linear
gradient to A/B:70/30 within 5 min. Data were normalized to the
internal standard PGB1, which allows the comparison of signal
intensities between samples but not absolute quantification.
To quantify lipid mediators and fatty acids in macrophages, murine
plasma, and murine peritoneal exudates, the mobile phase methanol/
H2O (acidified with 0.01% acetic acid) was ramped from 42:58 to
86:14 over 12.5 min, followed by isocratic elution with methanol/
H2O (98:2) for 3 min. Absolute quantification was based on 6
internal and 45 external standards.23
LCMs, 27a, and 27a metabolites were separated at a flow rate of
0.8 mL/min and a column temperature of 45 °C, with acetonitrile/
H2O (10:90) as mobile phase A and acetonitrile as mobile phase B,
both acidified with 0.07% formic acid. The linear gradient from A/B =
50:50 to 0:100 within 4.5 min was followed by isocratic elution with
A/B = 0:100 for 1 min. MS parameters were adjusted according to
Pein et al.6 and as detailed in Table S3. Signal intensities were
normalized to the internal standard 13d, and concentrations were
calculated using external calibration curves as specified in Table S3.
Automatic peak integration was performed with Analyst 1.6
software (Sciex) using IntelliQuan default settings.
Correlation Network Analysis. The structure-based correlation
networks of LCMs and derivatives were generated with Cytoscape
3.7.2 software (Cytoscape Consortium).84 Tanimoto coefficients were
calculated between the SMILES structures of compounds and
represent the connecting edges in the correlation network, which is
presented in an edge-weighted spring embedded layout. Nodes in
close proximity represent structurally related compounds. The
potency of the compounds to inhibit cell-free or cell-based 5-LOX
activity is visualized by the node size, where bigger nodes represent
compounds with higher inhibitory activity (lower IC50 value). The
node shape illustrates the compound series, and the node color
indicates the series of garcinoic acids (13a-e), amplexichromanols
(27a−d), tocopherols, and tocotrienols (1a−d, 6a−d).
Multiorgan-Tissue-Flow (MOTiF) Biochips. Biochips were
made from polystyrene by injection molding and were equipped
with a poly(ethylene terephthalate) (PET) membrane (TRAKETCH,
thickness: 12 μm; pore diameter: 8 μm; pore density: 1 × 105 pores/
cm2; Sabeu, Radeberg, Germany) that was integrated in the upper and
lower parts of the biochip by heat-sealing with the bulk material. The
top and bottom sides of the biochips and channels were sealed with
an extruded PS bonding foil (thickness: 125 μm) by a low-
temperature bonding method. The upper and lower parts of the
biochips were assembled using a double-sided adhesive film, and the
chip surface was hydrophilized by oxygen plasma treatment to
facilitate cell adhesion and prevent air bubble formation within the
chambers and channels.85,86
HUVECs were isolated from human umbilical cord veins and
cultivated in an endothelial cell growth medium MV (Promocell,
Heidelberg, Germany) with penicillin (100 U/mL)/streptomycin
(100 μg/mL, GE Healthcare) up to passage 4.87 On reaching 95%
confluence, cells were subcultured at a density of 1.5 × 104 cells/cm2.
HepaRG cells (Biopredic International, Rennes, France) were
grown in William’s medium E (Biochrom, Berlin, Germany) with 10%
FCS, 5 μg/mL insulin (Sigma-Aldrich), 2 mM glutamine (Thermo
Fisher Scientific), 50 μM hydrocortisone-hemisuccinate (Sigma-
Aldrich), and penicillin (100 U/mL)/streptomycin (100 μg/mL,
GE Healthcare) at 37 °C and 5% CO2 for 14 days prior to
differentiation with 2% DMSO for another 14 days. The medium was
changed every 3−4 days, and differentiated cells were used up to 4
weeks.
The liver-on-chip was prepared by seeding HUVECs (top: 3 × 105,
bottom: 1.5 × 105) in an endothelial cell growth medium MV on top
of the membrane in the upper chamber and on the bottom of the
membrane in the lower chamber, giving the cells 3−4 h to adhere
before flipping the chip upside and seeding the bottom layer. After 2
days, differentiated HepaRG cells (3 × 105) were seeded on top of the
lower and on the bottom of the upper membrane in a hepatocyte
culture medium with hydrocortisone-hemisuccinate adjusted to 5 μM
for 24 h at 37 °C and 5% CO2. The medium between the two
membranes was renewed, and the vehicle (DMSO), 12a, or 27a were
added. After incubation for 48 h at 37 °C and 5% CO2, the medium
was collected and the system was washed with 500 μL of methanol.
12a, 27a, and their metabolites were extracted from the combined
fractions and analyzed by UPLC-MS/MS.6
CYP3A4 Expression in Hepatocytes. HepaRG cells were seeded
at a density of 2.6 × 104 cells/cm2 in Williams’ E medium
supplemented with 2 mM GlutaMAX (Thermo Fisher Scientific,
Waltham, MA), 100 U/mL penicillin, 100 μg/mL streptomycin, 10%
HyClone FCS (Thermo Fisher Scientific), 5 μg/mL insulin, and 50
mM hydrocortisone-hemisuccinate. At confluence after two weeks,
HepaRG cells were shifted to a medium supplemented with 1.7%
DMSO for two additional weeks to obtain confluent differentiated
cultures containing equal proportions of hepatocyte-like and
progenitors/primitive biliary-like cells. These differentiated hepatic
cell cultures were exposed to the compounds in Williams’ E medium
supplemented with 2% FCS plus 0.2% DMSO for 48 h.
For immunolocalization of cytochrome CYP3A4 and F-actin, cells
were fixed at 4 °C with 4% paraformaldehyde for 20 min and
permeabilized for 30 min with 0.1% saponin in PBS pH 7.4 containing
5% donkey serum. Cells were washed with PBS and incubated for 90
min with the CYP3A4 primary antibody (AB1254, Chemicon
International, Temecula, CA) diluted at 1/800 in PBS containing
0.1% saponin and, then, incubated for 45 min with an FITC-labeled
secondary antibody (Jackson ImmunoResearch, West Grove, PA)
diluted at 1/400 in 0.1% saponin. F-actin was labeled by the
phalloidin fluoroprobe SR101 (200 U/mL) (Interchim, Montluco̧n,
France) diluted at 1/100 for 20 min.
The assay plate was imaged and analyzed using the Cell Health
Profiling BioApplications (HCS Studio Cellomics software Version
x.6.4.3 (Build 7207)) on the ArrayScan VTI HCS Reader (Thermo
Fisher ScientificCellomics, Pittsburgh, PA) using the 20× objective
(Zeiss, LD Plan Neofluar 20×/0.4 korr). Images were acquired with
the Photometrics X1 CCD camera with a 14-bit dynamic range, 2208
× 2208 pixel array, and 4.54 μm pixel size.
The CYP3A4 expression was quantified using an arbitrary unit of
fluorescent mass representing the combination of intensity and area
adjusted to cell number calculated by nuclei counting (Hoechst).
Experimental Atopic Dermatitis. Compound 27a was evaluated
in an inflammatory model of RHE by Synelvia S.A.S. (Labeg̀e,
France) according to the company’s protocol.88 In brief, primary
female human keratinocytes were used to generate RHE on
polycarbonate filters as described.88 RHE was allowed to acclimate
for 6 days (5% CO2, 37 °C) prior to incubation with 27a (5, 10, 25
μM), dexamethasone (1 μM), or vehicle (0.05% DMSO), and a
proinflammatory cytokine cocktail for 4 days at 5% CO2 and 37 °C.
The culture medium including compounds and cytokines was
changed on days 6, 8, and 10. Each culture condition was repeated
three times. Acute cytotoxicity of 27a was excluded at the
concentrations studied within 24 h by measuring the mitochondrial
dehydrogenase activity (MTT assay).
Morphological changes (i.e., spongiosis and the formation of
keratohyalin granules) were evaluated for sections of paraffin-
embedded RHEs after hematoxylin-eosin staining.89 The permeability
of the skin barrier was estimated from the transepidermal water loss at
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the RHE surface.90 The surface pH was determined with a pH
electrode as reported.89 The permeability of the stratum corneum was
addressed by applying Lucifer yellow onto the RHE surface and
inspecting the penetration by fluorescence microscopy.88 TSLP and
IL-8 levels were analyzed by ELISA (according to the specifications of
Synelvia S.A.S.) in the culture medium on day 2 and day 4 after
addition of cytokines, respectively.
Animals. Male CD-1 mice (33−39 g, 6−8 weeks, Charles River
Laboratories; Calco, Italy) and female BALB/c mice (20 g, 8 weeks,
Charles River Laboratories) were fed with standard rodent chow and
water and acclimated for 4 days at a 12 h light and 12 h dark schedule
in a constant air-conditioned environment (21 ± 2 °C). Mice were
randomly assigned to groups, and experiments were carried out
during the light phase. Experimental procedures were conducted in
conformity with Italian (DL 26/2014) and European (directive 2010/
63/EU) regulations on the protection of animals used for scientific
purposes and approved by the Italian Ministry.
Zymosan-Induced Peritonitis in Mice. CD-1 mice received 27a
or zileuton, with DMSO (2%) in saline (0.5 mL) as a vehicle for i.p.
administration and carboxymethylcellulose (0.5%) in 10% Tween 20
(0.5 mL) as a vehicle for p.o. administration. Zymosan (2 mg/mL in
saline, i.p., 0.5 mL, Sigma-Aldrich) was injected at 30 min (i.p.) or 60
min (p.o.) post compound administration. Mice were sacrificed by
inhalation of CO2 after another 30 min to determine LTC4 levels,
lipid mediator profiles, metabolites, and vascular permeability and
after 4 h to analyze LTB4 levels and cell infiltration.
72 Plasma and
peritoneal exudates were collected, and cells were counted in exudates
after trypan blue staining. Vascular permeability was measured by
injection of Evans blue dye (40 mg/kg in saline, 0.3 mL, Sigma-
Aldrich) into the tail vain directly before peritonitis induction.72 The
exudate was centrifuged (3000g, 5 min), and the absorbance was
measured at 610 nm (DU730 spectrophotometer, Beckman Coulter,
Krefeld, Germany). Levels of LTB4 and cysteinyl-LTs (dominated by
LTC4) were quantified in the exudate by ELISA (Enzo Life Sciences,
Lörrach, Germany) according to the manufacturer’s instructions.
Compound 27a, its metabolites, and lipid mediators were extracted
and analyzed by UPLC-MS/MS.
Experimental Model of Murine Asthma. BALB/c mice
received 27a (p.o.) or vehicle (0.5% carboxymethylcellulose in 10%
Tween 20; 0.5 mL) on days 0 and 7, 1 h (p.o) before being sensitized
to ovalbumin (100 μg adsorbed to 3.3 mg of aluminum hydroxide gel,
s.c., Sigma-Aldrich). Mice were sacrificed on days 1, 3, 8, 10, or 21 to
collect lung and plasma. Bronchi were cut in rings of 1 to 2 mm
length, placed in organ baths, and fixed to an isometric force
transducer 7006 connected to a Powerlab 800 (AD Instruments, Ugo
Basile, Comerio, Italy). After stretching the rings to a resting tension
of 0.5g and equilibration for at least 30 min, the rings were challenged
with carbachol (1 μM) until a reproducible response was observed.
To assess bronchial reactivity, the cumulative response to carbachol
(0.001 to 3.16 μM) was measured. Bronchial relaxation was
determined from the cumulative response of precontracted bronchial
tissues to salbutamol. Compound 27a, LTB4, and LTB4 isomers were
analyzed in plasma and lung homogenates by UPLC-MS/MS. Lung
tissue (100 mg/mL) was homogenized in PBS pH 7.4 at 4 °C for 1−2
min using an Omni tissue homogenizer (Omni, Kennesaw, GA).
Statistics. Data are presented as mean with single values or mean
± SEM of n observations, where n represents the number of
experiments or the number of animals, as indicated. The compound
library was blinded for screening purposes but not for further
biological evaluation, and samples from mouse peritoneum were
blinded for counting infiltrated cells. Outliers were identified using a
Grubb’s test. Different groups were compared by one-way or two-way
ANOVA for independent or correlated samples followed by Tukey’s
or Bonferroni’s HSD post hoc test or by the two-tailed Student’s t-test
for paired or unpaired samples. Tests were conducted using a two-
sided α level of 0.05. P values <0.05 were considered statistically
significant. Statistical calculations were performed using GraphPad
Prism 9.1 (GraphPad Software, La Jolla, CA). IC50 values were
determined by graphical analysis using SigmaPlot 14.0 (Systat
Software Inc., San Jose, CA).
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■ ABBREVIATIONS USED
COX, cyclooxygenase; cPLA2, cytosolic phospholipase A2;
DPPH, 2,2-diphenyl-1-picrylhydrazyl; FLAP, 5-lipoxygenase-
activating protein; fMLP, N-formyl-methionyl-leucyl-phenyl-
alanine; H(P)ETE, hydro(pero)xyeicosatetraenoic acid;
HDHA, hydroxydocosahexaenoic acid; HEPE, hydroxyeicosa-
pentaenoic acid; HETE, hydroxyeicosatetraenoic acid;
HUVEC, human umbilical vein endothelial cells; IL,
interleukin; iNOS, inducible nitric oxide synthase; LCM,
long-chain vitamin E metabolite; LDH, lactate dehydrogenase;
LOX, lipoxygenase; LPS, lipopolysaccharide; LT, leukotriene;
mPGES-1, microsomal prostaglandin E2 synthase-1; MTT, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
NAFLD, nonalcoholic fatty liver disease; PBMC, peripheral
blood mononuclear cells; PG, prostaglandin; PMNL, poly-
morphonuclear leukocytes; RHE, reconstructed human epi-
dermis; sEH, soluble expoxide hydrolase; TSLP, thymic
stromal lymphopoietin
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